US20120010168A1 - Unique Dual-Action Therapeutics - Google Patents
Unique Dual-Action Therapeutics Download PDFInfo
- Publication number
- US20120010168A1 US20120010168A1 US13/127,284 US200913127284A US2012010168A1 US 20120010168 A1 US20120010168 A1 US 20120010168A1 US 200913127284 A US200913127284 A US 200913127284A US 2012010168 A1 US2012010168 A1 US 2012010168A1
- Authority
- US
- United States
- Prior art keywords
- phenyl
- methyl
- nsaid
- compound
- carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title abstract description 16
- 230000009977 dual effect Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 21
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 20
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 18
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims abstract description 16
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 15
- 229960000905 indomethacin Drugs 0.000 claims abstract description 14
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 13
- 229960002009 naproxen Drugs 0.000 claims abstract description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 12
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001259 diclofenac Drugs 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 75
- -1 phenyl 3,3-dimethylbutyl carbonate Chemical compound 0.000 claims description 32
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 12
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 12
- 230000009467 reduction Effects 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 11
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 8
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 7
- 238000010168 coupling process Methods 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- MXRPYJXCVPZEMT-UHFFFAOYSA-N [4-(2-trimethylsilylethoxycarbonyloxy)phenyl]methyl 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OCC1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 MXRPYJXCVPZEMT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 4
- 238000006073 displacement reaction Methods 0.000 claims description 4
- RBYHDOCLSOQXRC-UHFFFAOYSA-N 2-trimethylsilylethyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OCC[Si](C)(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 RBYHDOCLSOQXRC-UHFFFAOYSA-N 0.000 claims description 3
- WSSFTSUIBUXGAZ-UHFFFAOYSA-N 2-trimethylsilylethyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound C[Si](C)(C)CCOC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl WSSFTSUIBUXGAZ-UHFFFAOYSA-N 0.000 claims description 3
- RPLWYFHASHPJRJ-UHFFFAOYSA-N 2-trimethylsilylethyl 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound CC(C)CC1=CC=C(C(C)C(=O)OCC[Si](C)(C)C)C=C1 RPLWYFHASHPJRJ-UHFFFAOYSA-N 0.000 claims description 3
- FFAZIHFCWAPFNS-UHFFFAOYSA-N 3,3-dimethylbutyl 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OCCC(C)(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FFAZIHFCWAPFNS-UHFFFAOYSA-N 0.000 claims description 3
- ASQXDEJVNKEPTG-UHFFFAOYSA-N 3,3-dimethylbutyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound CC(C)(C)CCOC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl ASQXDEJVNKEPTG-UHFFFAOYSA-N 0.000 claims description 3
- NERRITGZBNKUDJ-UHFFFAOYSA-N 3,3-dimethylbutyl 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound CC(C)CC1=CC=C(C(C)C(=O)OCCC(C)(C)C)C=C1 NERRITGZBNKUDJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- LKNKZYQBLHALFU-UHFFFAOYSA-N [4-(2-trimethylsilylethoxycarbonyloxy)phenyl]methyl 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 LKNKZYQBLHALFU-UHFFFAOYSA-N 0.000 claims description 3
- LXBFPRSQOWRVRJ-UHFFFAOYSA-N [4-(3,3-dimethylbutoxycarbonyloxy)phenyl]methyl 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 LXBFPRSQOWRVRJ-UHFFFAOYSA-N 0.000 claims description 3
- PIKDJKQZJYTMBP-UHFFFAOYSA-N [4-(3-methylbutoxycarbonyloxy)phenyl]methyl 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OCC1=CC=C(OC(=O)OCCC(C)C)C=C1 PIKDJKQZJYTMBP-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- FJVADGXAIDQKOI-UHFFFAOYSA-M 2-[2-(6-methoxynaphthalen-2-yl)propanoyloxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C1=C(C(C)C(=O)OCC[N+](C)(C)C)C=CC2=CC(OC)=CC=C21 FJVADGXAIDQKOI-UHFFFAOYSA-M 0.000 claims description 2
- TZKVPPMDTCPZAQ-UHFFFAOYSA-N 2-[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]oxyethyl-trimethylazanium Chemical compound CC1=C(CC(=O)OCC[N+](C)(C)C)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 TZKVPPMDTCPZAQ-UHFFFAOYSA-N 0.000 claims description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims description 2
- ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 claims description 2
- IJIOVNARPLXKAK-UHFFFAOYSA-N 2-trimethylsilylethoxycarbonyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound C[Si](C)(C)CCOC(=O)OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl IJIOVNARPLXKAK-UHFFFAOYSA-N 0.000 claims description 2
- ZNDRMBGZDWQVIT-AWEZNQCLSA-N 2-trimethylsilylethyl (2s)-2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C([C@H](C)C(=O)OCC[Si](C)(C)C)C=CC2=CC(OC)=CC=C21 ZNDRMBGZDWQVIT-AWEZNQCLSA-N 0.000 claims description 2
- YQWUIWSRXREORA-UHFFFAOYSA-N 3,3-dimethylbutoxycarbonyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound CC(C)(C)CCOC(=O)OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl YQWUIWSRXREORA-UHFFFAOYSA-N 0.000 claims description 2
- LFMBWAUXQZDEPK-AWEZNQCLSA-N 3,3-dimethylbutyl (2s)-2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C([C@H](C)C(=O)OCCC(C)(C)C)C=CC2=CC(OC)=CC=C21 LFMBWAUXQZDEPK-AWEZNQCLSA-N 0.000 claims description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- PZWSSADDCPREPY-UHFFFAOYSA-N [4-(3,3-dimethylbutoxycarbonyloxy)phenyl]methyl 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 PZWSSADDCPREPY-UHFFFAOYSA-N 0.000 claims description 2
- BLOXCTQYQTYRPH-UHFFFAOYSA-N [4-[3-[2-(2,6-dichloroanilino)phenyl]-2-oxopropyl]phenyl] 2-trimethylsilylethyl carbonate Chemical compound C1=CC(OC(=O)OCC[Si](C)(C)C)=CC=C1CC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl BLOXCTQYQTYRPH-UHFFFAOYSA-N 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- YCSSAISHORSXBR-UHFFFAOYSA-N trimethyl-[2-[2-[4-(2-methylpropyl)phenyl]propanoyloxy]ethyl]azanium Chemical compound CC(C)CC1=CC=C(C(C)C(=O)OCC[N+](C)(C)C)C=C1 YCSSAISHORSXBR-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000002352 blister Diseases 0.000 claims 3
- 230000035901 vesication Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- LVLNPXCISNPHLE-UHFFFAOYSA-N 2-[(4-hydroxyphenyl)methyl]phenol Chemical compound C1=CC(O)=CC=C1CC1=CC=CC=C1O LVLNPXCISNPHLE-UHFFFAOYSA-N 0.000 claims 1
- DUXCSEISVMREAX-UHFFFAOYSA-N 3,3-dimethylbutan-1-ol Chemical compound CC(C)(C)CCO DUXCSEISVMREAX-UHFFFAOYSA-N 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract description 24
- 150000002148 esters Chemical class 0.000 abstract description 23
- 239000003112 inhibitor Substances 0.000 abstract description 22
- 229940022698 acetylcholinesterase Drugs 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 230000002441 reversible effect Effects 0.000 abstract description 5
- 230000001713 cholinergic effect Effects 0.000 abstract description 4
- 238000013270 controlled release Methods 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 131
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 47
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- 238000002360 preparation method Methods 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000003756 stirring Methods 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 102100033639 Acetylcholinesterase Human genes 0.000 description 23
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 239000000651 prodrug Substances 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 238000006460 hydrolysis reaction Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 0 [2H]*/S(I)=N/C(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 Chemical compound [2H]*/S(I)=N/C(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 0.000 description 14
- 230000007062 hydrolysis Effects 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- VPBKCEFQEGMUOG-UHFFFAOYSA-N 3,3-dimethylbutyl [4-(hydroxymethyl)phenyl] carbonate Chemical compound CC(C)(C)CCOC(=O)OC1=CC=C(CO)C=C1 VPBKCEFQEGMUOG-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- XOHQUEWPBVOKLV-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl] 2-trimethylsilylethyl carbonate Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1 XOHQUEWPBVOKLV-UHFFFAOYSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CLVMYFAAZJELSZ-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl] hydrogen carbonate Chemical compound OCC1=CC=C(OC(O)=O)C=C1 CLVMYFAAZJELSZ-UHFFFAOYSA-N 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- FXEDIXLHKQINFP-UHFFFAOYSA-N 12-O-tetradecanoylphorbol-13-acetate Natural products CCCCCCCCCCCCCC(=O)OC1CC2(O)C(C=C(CO)CC3(O)C2C=C(C)C3=O)C4C(C)(C)C14OC(=O)C FXEDIXLHKQINFP-UHFFFAOYSA-N 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 5
- 150000001805 chlorine compounds Chemical class 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- CEGMHVNKOJAJTM-UHFFFAOYSA-N 3,3-dimethylbutyl (4-formylphenyl) carbonate Chemical compound CC(C)(C)CCOC(=O)OC1=CC=C(C=O)C=C1 CEGMHVNKOJAJTM-UHFFFAOYSA-N 0.000 description 4
- STRCBZDANZKUTB-UHFFFAOYSA-N CC(C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1 Chemical compound CC(C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1 STRCBZDANZKUTB-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- BTEQQLFQAPLTLI-UHFFFAOYSA-N 2-trimethylsilylethyl carbonochloridate Chemical compound C[Si](C)(C)CCOC(Cl)=O BTEQQLFQAPLTLI-UHFFFAOYSA-N 0.000 description 3
- KCCKTIKZOIPZTG-UHFFFAOYSA-N 3-methylbutyl carbonochloridate Chemical compound CC(C)CCOC(Cl)=O KCCKTIKZOIPZTG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007073 chemical hydrolysis Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 239000000544 cholinesterase inhibitor Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- UODROGXCIVAQDJ-VIFPVBQESA-N (2s)-2-(6-methoxynaphthalen-2-yl)propanoyl chloride Chemical compound C1=C([C@H](C)C(Cl)=O)C=CC2=CC(OC)=CC=C21 UODROGXCIVAQDJ-VIFPVBQESA-N 0.000 description 2
- CFKFYTNCCWUQQE-UHFFFAOYSA-N (4-formylphenyl) 2-trimethylsilylethyl carbonate Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(C=O)C=C1 CFKFYTNCCWUQQE-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- TUZRJGVLAFMQEK-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 TUZRJGVLAFMQEK-UHFFFAOYSA-N 0.000 description 2
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 2
- NRBNZNCJPSFQAQ-UHFFFAOYSA-N 3,3-dimethylbutyl carbonochloridate Chemical compound CC(C)(C)CCOC(Cl)=O NRBNZNCJPSFQAQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- PZWSSADDCPREPY-IBGZPJMESA-N COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCCC(C)(C)C)C=C3)C=CC2=C1 Chemical compound COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCCC(C)(C)C)C=C3)C=CC2=C1 PZWSSADDCPREPY-IBGZPJMESA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- WJPFWQBKZKBYHF-UHFFFAOYSA-N [4-(chloromethyl)phenyl] 2-trimethylsilylethyl carbonate Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(CCl)C=C1 WJPFWQBKZKBYHF-UHFFFAOYSA-N 0.000 description 2
- CRZMOJRMSLUVJP-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl] 3-methylbutyl carbonate Chemical compound CC(C)CCOC(=O)OC1=CC=C(CO)C=C1 CRZMOJRMSLUVJP-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000006959 non-competitive inhibition Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002717 polyvinylpyridine Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000006965 reversible inhibition Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960003565 tacrine hydrochloride Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VKFLQHNSBFAXRF-UHFFFAOYSA-N (4-formylphenyl) 3-methylbutyl carbonate Chemical compound CC(C)CCOC(=O)OC1=CC=C(C=O)C=C1 VKFLQHNSBFAXRF-UHFFFAOYSA-N 0.000 description 1
- GBNVXYXIRHSYEG-UHFFFAOYSA-N 1-chloro-2-ethylsulfanylethane Chemical compound CCSCCCl GBNVXYXIRHSYEG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QXVRLFIKHYCFJS-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanoyl chloride Chemical compound CC(C)CC1=CC=C(C(C)C(Cl)=O)C=C1 QXVRLFIKHYCFJS-UHFFFAOYSA-N 0.000 description 1
- IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- QNBZBQZEELNQPW-UHFFFAOYSA-L 2-hydroxyethyl(trimethyl)azanium;carbonate Chemical class [O-]C([O-])=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO QNBZBQZEELNQPW-UHFFFAOYSA-L 0.000 description 1
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical compound C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 description 1
- RUHPVABIDKCXIA-UHFFFAOYSA-N 3,5-dimethoxy-4-(3-methylbut-2-enoxy)benzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OCC=C(C)C RUHPVABIDKCXIA-UHFFFAOYSA-N 0.000 description 1
- IWTBVKIGCDZRPL-LURJTMIESA-N 3-Methylbutanol Natural products CC[C@H](C)CCO IWTBVKIGCDZRPL-LURJTMIESA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001656913 Buxus balearica Species 0.000 description 1
- BXDQSBMVNRNWCY-UHFFFAOYSA-M CC(=O)OC1=CC=C(COC(=O)C(C)C2=CC=C(CC(C)C)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(O)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(OC(=O)OCCN(C)(C)C)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(OC(=O)OCCN(C)C)C=C2)C=C1.[I-] Chemical compound CC(=O)OC1=CC=C(COC(=O)C(C)C2=CC=C(CC(C)C)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(O)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(OC(=O)OCCN(C)(C)C)C=C2)C=C1.CC(C)CC1=CC=C(C(C)C(=O)OCC2=CC=C(OC(=O)OCCN(C)C)C=C2)C=C1.[I-] BXDQSBMVNRNWCY-UHFFFAOYSA-M 0.000 description 1
- LVELYMFAJYGSSJ-UHFFFAOYSA-N CC(C)(C)C.CC1=CC=C2C=C(C(C)C(=O)O)C=CC2=C1.CC1=CC=C2C=C(C(C)C(=O)OCC3=CC=C(OC(=O)OCC[Si](C)(C)C)C=C3)C=CC2=C1.CC1=CC=C2C=C(C(C)C(=O)[Ag])C=CC2=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(CCl)C=C1 Chemical compound CC(C)(C)C.CC1=CC=C2C=C(C(C)C(=O)O)C=CC2=C1.CC1=CC=C2C=C(C(C)C(=O)OCC3=CC=C(OC(=O)OCC[Si](C)(C)C)C=C3)C=CC2=C1.CC1=CC=C2C=C(C(C)C(=O)[Ag])C=CC2=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(CCl)C=C1 LVELYMFAJYGSSJ-UHFFFAOYSA-N 0.000 description 1
- HNYCFJKYNVHKMU-UHFFFAOYSA-N CC(C)(C)CCO.CC(C)(C)CCOC(=O)Cl.O=C(Cl)Cl Chemical compound CC(C)(C)CCO.CC(C)(C)CCOC(=O)Cl.O=C(Cl)Cl HNYCFJKYNVHKMU-UHFFFAOYSA-N 0.000 description 1
- YIPFMYQXVFCXNW-UHFFFAOYSA-N CC(C)(C)CCO.CC(C)(C)CCOC(=O)Cl.O=C(OC(Cl)(Cl)Cl)OC(Cl)(Cl)Cl Chemical compound CC(C)(C)CCO.CC(C)(C)CCOC(=O)Cl.O=C(OC(Cl)(Cl)Cl)OC(Cl)(Cl)Cl YIPFMYQXVFCXNW-UHFFFAOYSA-N 0.000 description 1
- JMQJKQDKAQZUNB-UHFFFAOYSA-N CC(C)(C)CCOC(=O)Cl.CCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1.OCC1=CC=C(O)C=C1 Chemical compound CC(C)(C)CCOC(=O)Cl.CCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1.OCC1=CC=C(O)C=C1 JMQJKQDKAQZUNB-UHFFFAOYSA-N 0.000 description 1
- WITFYIGZHFKEQF-UHFFFAOYSA-N CC(C)(C)CCOC(=O)Cl.[H]C(=O)C1=CC=C(O)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 Chemical compound CC(C)(C)CCOC(=O)Cl.[H]C(=O)C1=CC=C(O)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 WITFYIGZHFKEQF-UHFFFAOYSA-N 0.000 description 1
- JJSGWWDUQIRTDE-UHFFFAOYSA-N CC(C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 Chemical compound CC(C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)(C)C)C=C1 JJSGWWDUQIRTDE-UHFFFAOYSA-N 0.000 description 1
- KRJNPTVEOYHDEA-UHFFFAOYSA-N CC(C)CC1=CC=C(C(C)C(=O)Cl)C=C1.CC(C)CC1=CC=C(C(C)C(=O)O)C=C1 Chemical compound CC(C)CC1=CC=C(C(C)C(=O)Cl)C=C1.CC(C)CC1=CC=C(C(C)C(=O)O)C=C1 KRJNPTVEOYHDEA-UHFFFAOYSA-N 0.000 description 1
- DXOILSMFFBQFEW-UHFFFAOYSA-M CC(C)CC1=CC=C(C(C)C(=O)OCCN(C)(C)C)C=C1.[I-] Chemical compound CC(C)CC1=CC=C(C(C)C(=O)OCCN(C)(C)C)C=C1.[I-] DXOILSMFFBQFEW-UHFFFAOYSA-M 0.000 description 1
- XETIBEUZGXVGSC-UHFFFAOYSA-N CC(C)CCOC(=O)Cl.CC(C)CCOC(=O)OC1=CC=C(C(=O)I)C=C1.[H]C(=O)C1=CC=C(O)C=C1 Chemical compound CC(C)CCOC(=O)Cl.CC(C)CCOC(=O)OC1=CC=C(C(=O)I)C=C1.[H]C(=O)C1=CC=C(O)C=C1 XETIBEUZGXVGSC-UHFFFAOYSA-N 0.000 description 1
- RKLBPPUTWCVABB-WNLAAKBOSA-N CC(C)CCOC(=O)OC1=CC=C(CO)C=C1.COC1=CC=C2C=C([C@H](C)C(=O)Cl)C=CC2=C1.COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCCC(C)C)C=C3)C=CC2=C1 Chemical compound CC(C)CCOC(=O)OC1=CC=C(CO)C=C1.COC1=CC=C2C=C([C@H](C)C(=O)Cl)C=CC2=C1.COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCCC(C)C)C=C3)C=CC2=C1 RKLBPPUTWCVABB-WNLAAKBOSA-N 0.000 description 1
- JKSZPFDNMQBLFD-UHFFFAOYSA-N CC(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)C)C=C1 Chemical compound CC(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCCC(C)C)C=C1 JKSZPFDNMQBLFD-UHFFFAOYSA-N 0.000 description 1
- FGXLWUNHIIASGU-UHFFFAOYSA-N CC(C)CCOC(Oc(cc1)ccc1C(I)=O)=O Chemical compound CC(C)CCOC(Oc(cc1)ccc1C(I)=O)=O FGXLWUNHIIASGU-UHFFFAOYSA-N 0.000 description 1
- SBILAYAIIIIVOZ-HNNXBMFYSA-N CC1=CC=C2C=C([C@H](C)C(=O)OCCC(C)(C)C)C=CC2=C1 Chemical compound CC1=CC=C2C=C([C@H](C)C(=O)OCCC(C)(C)C)C=CC2=C1 SBILAYAIIIIVOZ-HNNXBMFYSA-N 0.000 description 1
- RZPPABCWAIGGFP-RSAXXLAASA-M CC1=CC=C2C=C([C@H](C)C(=O)OCCN(C)(C)C)C=CC2=C1.[I-] Chemical compound CC1=CC=C2C=C([C@H](C)C(=O)OCCN(C)(C)C)C=CC2=C1.[I-] RZPPABCWAIGGFP-RSAXXLAASA-M 0.000 description 1
- XNLUNBMTRHFSHD-HNNXBMFYSA-N CC1=CC=C2C=C([C@H](C)C(=O)OCC[Si](C)(C)C)C=CC2=C1 Chemical compound CC1=CC=C2C=C([C@H](C)C(=O)OCC[Si](C)(C)C)C=CC2=C1 XNLUNBMTRHFSHD-HNNXBMFYSA-N 0.000 description 1
- SUQAOTJRLBQCRO-UHFFFAOYSA-N CN(C)CCO.[Li]OCCN(C)C Chemical compound CN(C)CCO.[Li]OCCN(C)C SUQAOTJRLBQCRO-UHFFFAOYSA-N 0.000 description 1
- ZEWSATSGSYXSAD-UHFFFAOYSA-N COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)Cl.COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)O.O=C(Cl)C(=O)Cl Chemical compound COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)Cl.COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)O.O=C(Cl)C(=O)Cl ZEWSATSGSYXSAD-UHFFFAOYSA-N 0.000 description 1
- CIYDJUDCVBIVOT-UHFFFAOYSA-M COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCCN(C)(C)C.[I-] Chemical compound COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCCN(C)(C)C.[I-] CIYDJUDCVBIVOT-UHFFFAOYSA-M 0.000 description 1
- DHVSCTXXPREERV-UHFFFAOYSA-N COC1=CC=C2C(=C1)C(CC(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1 Chemical compound COC1=CC=C2C(=C1)C(CC(=O)OCC1=CC=C(OC(=O)OCCC(C)(C)C)C=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1 DHVSCTXXPREERV-UHFFFAOYSA-N 0.000 description 1
- QKXSBFSFNAGYHX-UHFFFAOYSA-N COC1=CC=C2C(=C1)C(CC(=O)OCC1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1 Chemical compound COC1=CC=C2C(=C1)C(CC(=O)OCC1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1)=C(C)N2C(=O)C1=CC=C(Cl)C=C1 QKXSBFSFNAGYHX-UHFFFAOYSA-N 0.000 description 1
- BPIHYXAWBGJFSF-XFNAGHOKSA-N COC1=CC=C2C=C([C@H](C)C(=O)Cl)C=CC2=C1.COC1=CC=C2C=C([C@H](C)C(=O)O)C=CC2=C1 Chemical compound COC1=CC=C2C=C([C@H](C)C(=O)Cl)C=CC2=C1.COC1=CC=C2C=C([C@H](C)C(=O)O)C=CC2=C1 BPIHYXAWBGJFSF-XFNAGHOKSA-N 0.000 description 1
- MXRPYJXCVPZEMT-IBGZPJMESA-N COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCC[Si](C)(C)C)C=C3)C=CC2=C1 Chemical compound COC1=CC=C2C=C([C@H](C)C(=O)OCC3=CC=C(OC(=O)OCC[Si](C)(C)C)C=C3)C=CC2=C1 MXRPYJXCVPZEMT-IBGZPJMESA-N 0.000 description 1
- OIQVNCMYBADGJZ-UHFFFAOYSA-O C[SH+](C)(C)COC(Oc1ccc(CO)cc1)=O Chemical compound C[SH+](C)(C)COC(Oc1ccc(CO)cc1)=O OIQVNCMYBADGJZ-UHFFFAOYSA-O 0.000 description 1
- CLKQJIONKVUJBA-UHFFFAOYSA-N C[Si](C)(C)CCOC(=O)Cl.C[Si](C)(C)COC(=O)OC1=CC=C(COI)C=C1.OCC1=CC=C(O)C=C1 Chemical compound C[Si](C)(C)CCOC(=O)Cl.C[Si](C)(C)COC(=O)OC1=CC=C(COI)C=C1.OCC1=CC=C(O)C=C1 CLKQJIONKVUJBA-UHFFFAOYSA-N 0.000 description 1
- WGLMAUUTIHYXQQ-UHFFFAOYSA-N C[Si](C)(C)CCOC(=O)Cl.[H]C(=O)C1=CC=C(O)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 Chemical compound C[Si](C)(C)CCOC(=O)Cl.[H]C(=O)C1=CC=C(O)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 WGLMAUUTIHYXQQ-UHFFFAOYSA-N 0.000 description 1
- FDOFMPLXQBCQJQ-UHFFFAOYSA-N C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(COC(=O)CC2=C(NC3=C(Cl)C=CC=C3Cl)C=CC=C2)C=C1.O=C(O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1 Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.C[Si](C)(C)CCOC(=O)OC1=CC=C(COC(=O)CC2=C(NC3=C(Cl)C=CC=C3Cl)C=CC=C2)C=C1.O=C(O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1 FDOFMPLXQBCQJQ-UHFFFAOYSA-N 0.000 description 1
- TXKOGCKBMLLQDO-UHFFFAOYSA-N C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(CO)C=C1.[H]C(=O)C1=CC=C(OC(=O)OCC[Si](C)(C)C)C=C1 TXKOGCKBMLLQDO-UHFFFAOYSA-N 0.000 description 1
- VEKARYRFUSHVKO-UHFFFAOYSA-N C[Si](C)(C)CCOC(=O)OC1=CC=C(COC(=O)CC2=C(NC3=C(Cl)C=CC=C3Cl)C=CC=C2)C=C1.C[Si](C)(C)COC(=O)OC1=CC=C(CCl)C=C1.O=C(O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1 Chemical compound C[Si](C)(C)CCOC(=O)OC1=CC=C(COC(=O)CC2=C(NC3=C(Cl)C=CC=C3Cl)C=CC=C2)C=C1.C[Si](C)(C)COC(=O)OC1=CC=C(CCl)C=C1.O=C(O)CC1=C(NC2=C(Cl)C=CC=C2Cl)C=CC=C1 VEKARYRFUSHVKO-UHFFFAOYSA-N 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000489976 Diabrotica undecimpunctata howardi Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000277305 Electrophorus electricus Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000256244 Heliothis virescens Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- 229910004068 NO2Cl Inorganic materials 0.000 description 1
- RWUYTWHCJXCYIF-UHFFFAOYSA-O O=C(OCC[SH2+])Cl Chemical compound O=C(OCC[SH2+])Cl RWUYTWHCJXCYIF-UHFFFAOYSA-O 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- VVAQNAQSTNCJSQ-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl] hydrogen carbonate Chemical class OCC1=CC=CC=C1OC(O)=O VVAQNAQSTNCJSQ-UHFFFAOYSA-N 0.000 description 1
- SCBNOSPZFLKKSX-UHFFFAOYSA-N [4-(chloromethyl)phenyl] carbonochloridate Chemical compound ClCC1=CC=C(OC(Cl)=O)C=C1 SCBNOSPZFLKKSX-UHFFFAOYSA-N 0.000 description 1
- DXQOYBHADCHGTA-UHFFFAOYSA-N [4-(chloromethyl)phenyl] hydrogen carbonate Chemical class OC(=O)OC1=CC=C(CCl)C=C1 DXQOYBHADCHGTA-UHFFFAOYSA-N 0.000 description 1
- YAGBZSSJLMOFJP-UHFFFAOYSA-N [Li].CN(C)C(C)O Chemical compound [Li].CN(C)C(C)O YAGBZSSJLMOFJP-UHFFFAOYSA-N 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- MTMNJFGEKOYMIV-UHFFFAOYSA-N carbonyl dichloride;toluene Chemical compound ClC(Cl)=O.CC1=CC=CC=C1 MTMNJFGEKOYMIV-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 229950000405 decamethonium Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009066 down-regulation mechanism Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000058 esterolytic effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- This invention relates to a new class of reversible inhibitors of acetylcholinesterase (International Enzyme classification EC3.1.1.7) which serve simultaneously as pro-drugs capable of releasing non-steroidal anti-inflammatory agents (NSAIDs) by hydrolysis at either one or two chemically different hydrolytically-active loci.
- NSAIDs non-steroidal anti-inflammatory agents
- Inflammatory processes often amenable to address by non-steroidal anti-inflammatories such as ibuprofen, naproxen, indomethacin and diclofenac, are inherent in the pathologies of multiple sclerosis, Alzheimer's disease, depression, amyotrophic lateral sclerosis, dementia, Parkinson's disease, and other neurodegenerative states.
- ibuprofen ibuprofen
- naproxen ibuprofen
- indomethacin and diclofenac diclofenac
- indomethacin and other NSAIDs either in prophylaxis or in therapy risks adverse gastrointestinal effects, renal toxicity, allergic responses, and occasionally severe ulcerations.
- a highly lipophilic ester “pro-drug” of indomethacin [DP-155] has been claimed to deliver enhanced brain levels while markedly decreasing both renal and gastrointestinal toxicities (E. Dvir, A. Elmann, D. Simmons, I. Shapiro, R. Duvdevani, A. Dahan, A. Hoffman, and J. E. Friedman, CNS Drug Rev. 2007, 13: 260-277).
- the pro-drug conjugate was efficacious in reducing levels of amyloid ss (Ass) 42 in a transgenic Alzheimer's disease mouse (Tg2576).
- a methylene chain spacer separated the indomethacin ester from the ester at the lipid carrier terminus.
- a five carbon spacer was shown to be 20-fold better in transmembrane absorption than a short two-carbon spacer (A. Dahan, R. Duvdevani, E. Dvir, A. Elmann, and A. Hoffman, J. Control Release 2007, 119: 86-93).
- NSAID-esters of basic aminoalcohols are reported to be competitive reversible inhibitors of AChE and to reduce intestinal gastric ulceration often associated with the non-conjugated NSAID carboxylic acids or their salts (P. K. Halen, K. K. Chagti, R. Giridhar, and M. R. Yadav, Chem. Bio. Drug Des. 2007: 70: 450-455).
- the cholinergic anti-inflammatory pathway is a high value therapeutic target readily justifying the combination of anti-cholinergic and anti-inflammatory activity into a single molecule.
- Wang has noted that binding at the acetylcholine receptor is a down-regulatory mechanism for inflammation (H. Wang et al., Nature 2003, 421: 384-388).
- Amitai has shown that the combination of an anti-inflammatory (ibuprofen or diclofenac) and an inhibitor of acetylcholinesterase into the same molecule provided a therapeutic benefit in the treatment of inflammation resulting from chemical blistering agents (A. Amitai, R. Adani, E. Fishbein et al., J. Applied Tox., 2006, 26: 81-87).
- an NSAID an anti-cholinergic
- the two moieties could not be independently liberated in vivo.
- This application relates to a unique lipophilic pro-drug of an NSAID such as indomethacin (or other NSAIDs) which is simultaneously a competitive reversible inhibitor of acetylcholinesterase and a controlled release carrier of the NSAID.
- NSAID such as indomethacin
- These pharmaceuticals are unsymmetrical alkyl-aryl carbonates whose —O—CO—O— bond is readily cleaved both by chemical hydrolysis and esterolytic activity, thereby freeing an NSAID by a facilitated hydrolysis. Since the NSAID is directly attached to the platform by a hydrolyzable ester function, there are two modes by which the NSAID is made available.
- one embodiment of the invention relates to a compound of Formula 1 wherein
- n 0 or 1
- X is Si, C, or N + ;
- each R is alike or different and is hydrogen or (C 1 -C 6 ) alkyl
- NSAID is a non-steroidal anti-inflammatory agent.
- FIG. 1 shows a HPLC chromatogram obtained in chemical hydrolysis of the compound of Example 9.
- FIG. 2 shows a Lineweaver-Burk plot for reversible inhibition of acetylcholinesterase in absence and in presence of inhibitor Example 9 and 22 wherein the reciprocal of the velocity ⁇ (M min ⁇ 1 ) is plotted against the reciprocal of the substrate concentration s ( ⁇ M).
- FIG. 3 shows a HPLC chromatogram of the hydrolysis of Example 14 and release of parent NSAID after incubation in human plasma.
- ester-containing pro-drugs attractive targets as drug-delivery vehicles for topical or oral formulations (J. L. Prusakiewicz, C. Ackermann, and R. Voorman, Pharmaceutical Research 2006, 23: 1517-1524).
- Other studies have shown that a carbonate-linkage (—O—CO—O—) is always very similar in behavior to an ester-linkage as the hydrolysable function joining drug to carrier (J. Rautio et al., Nature Reviews Drug Discovery 2008, 7: 255-270).
- NO-ASA nitric oxide donating aspirin conjugate
- R in the structure shown above is aspirin (acetylsalicylic acid) linked at its carboxylic moiety and X is the NO-precursor —O—NO 2 .
- Promising results have been reported against colon, pancreatic, and breast cancers as well as in protection of gastric mucosal irritation and enhancement of in situ antioxidant events. (J. L. Williams, P. Ji, N. Ouyang, X. Liu, B. Rigas, Carcinogenesis 2008, 29, 390-397 and S. Kwiecien, M. W. Pawlik, T. Brzozowski, et al, J. Physiol Pharmacol. 2008 Suppl 2:103-15).
- these substances can be described as:
- T N + , Si, or C
- the structural shift from a water-soluble trimethyl ammonium [ + NMe 3 ] to a trimethyl carbon [—C(CH 3 ) 3 ] or to a trimethyl silyl [—Si(CH 3 ) 3 ] means an increasing hydrophobicity, these moieties can nevertheless by recognized and bound to acetylcholinesterase.
- this linker (when present) provides two sites of controlled hydrolytic/enzymatic release of the NSAID at a carbonate and at an ester functionality.
- composition containing a compound of Formula 1 may be administered in any variety of suitable forms, for example, parenterally, rectally, or orally. More specific routes of administration include intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, colonical, peritoneal, transepithelial including transdermal, ophthalmic, sublingual, buccal, dermal, ocular, nasal inhalation via insufflation, and aerosol.
- a composition containing a compound of Formula 1 may be presented in forms permitting administration by the most suitable route.
- the invention also relates to administering compositions containing a compound of Formula 1 which is suitable for use as a medicament in a patient.
- These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients.
- the adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents.
- the compositions may be presented in the form of oral dosage forms, or injectable solutions, or suspensions.
- vehicle and the compound of Formula 1 in the vehicle are generally determined in accordance with the solubility and chemical properties of the product, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
- aqueous suspensions When aqueous suspensions are used they may contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyols such as polyethylene glycol, propylene glycol and glycerol, and chloroform or mixtures thereof may also be used.
- the compound of Formula 1 may be incorporated into sustained-release preparations and formulations.
- emulsions, suspensions or solutions of the compounds according to the invention in vegetable oil for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts (when X is N + ), are used.
- the injectable forms must be fluid to the extent that it can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size, in the case of dispersion and by the use of surfactants.
- Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
- the solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection.
- Solutions of the neutral compound of Formula 1 wherein X is C or Si and pharmacologically acceptable salts of the subgenus of Formula 1 wherein X is N + can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose.
- Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.
- aqueous solutions also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation, microfiltration, and/or by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating the compound of Formula 1 in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze drying technique, which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- Topical administration gels (water or alcohol based), creams or ointments containing the compound of Formula 1 may be used.
- the compound of Formula 1 may be also incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through transdermal barrier.
- the percentage of compound of Formula 1 in the compositions used in the present invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. A dose employed may be determined by a physician or qualified medical professional, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient.
- the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 10, mg/kg body weight per day by intravenous administration.
- the doses are determined in accordance with the factors distinctive to the patient to be treated, such as age, weight, general state of health and other characteristics, which can influence the efficacy of the compound according to the invention.
- the compound of Formula 1 used in the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the compound of Formula 1 may be administered 1 to 4 times per day. Of course, for other patients, it will be necessary to prescribe not more than one or two doses per day.
- an acid chloride of the NSAID can be coupled to the appropriate p-hydroxymethylphenyl carbonate.
- NSAIDs used in this work were naproxen, ibuprofen, indomethacin, and diclofenac, but the method is general to the release of any other carboxyl terminated anti-inflammatory or other carboxyl-containing pharmaceuticals.
- the coupling of ibuprofen acid chloride to 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate is shown. Syntheses of the acid chlorides and the 4-(hydroxymethyl)phenyl carbonates as required in METHOD A is described below.
- the compounds are administered to patients by means known in the art including orally, parentally.
- the compounds of the invention are formulated as liquids, suspensions, tablets as is known in the art.
- METHOD A an NSAID converted to its acid chloride is coupled to 4-hydroxybenzaldehyde, the aldehyde reduced to a benzyl alcohol, and that alcohol condensed with an appropriate chloroformate (which had been prepared in a separate synthetic step) to give the objects of this invention, the final carbonate-esters, in overall yields of 22-45% for this five-step pathway.
- This variation of METHOD A is the Formyl Reduction Pathway.
- METHOD A the Direct Selective Acylation Pathway
- METHOD A uses pH and temperature control to condense the chloroformate specifically onto the phenolic —OH of p-hydroxybenzyl alcohol.
- This variation avoids the use of p-hydroxybenzaldehyde and shortens the synthesis by one step. This boosts the overall yields to 35-55%. Both pathways are discussed with specific examples below.
- a silicone oil bath was heated to 130° C.
- a reaction set-up was prepared consisting of a 200 mL round bottom flask with condenser and rubber septum-capped joints. After mixing the reactants as described below, the flask and contents were placed in the oil bath. Thionyl chloride (29.7 g, 0.25 mol) was added via glass syringe to 2-(4-isobutylphenyl)propionic acid (10.3 g, 0.05 mol) in dry toluene (60 mL) at room temperature under nitrogen atmosphere. The reaction mixture was then heated at 130° C. for 2.5 hr, removed from the oil bath, and allowed to cool to room temperature.
- Step 1 General Procedure for Preparation of Aliphatic Chloroformates with Either Triphosgene or Phosgene
- Triphosgene (0.75 moles) dissolved in 200 mL of anhydrous CH 2 Cl 2 was cooled to 0° C. and 1.0 moles of the corresponding aliphatic alcohol [X ⁇ C or Si] were added drop wise under nitrogen with stirring in a 500 mL round bottom fitted with condenser and pressure equalized side-arm dropping funnel. Then 1.20 moles of triethylamine in 50 mL of anhydrous methylene chloride were added drop wise while maintaining the reaction temperature below 4° C. When addition was complete, the solution was allowed to warm to 25° C. and the fluid was stirred for 16 hr. Anhydrous nitrogen gas was vigorously bubbled through the solution for 1 hr to purge it of excess triphosgene.
- phosgene gas (1.2 molar equivalents as a 20 wt % solution of phosgene in toluene).
- the phosgene-toluene was first cooled to ⁇ 8° C. to ⁇ 10° C. and then the aliphatic alcohols (1.0 molar equivalents in methylene chloride) are added drop wise followed by 1.2 molar equivalents of triethylamine.
- the reaction temperature was held at or below ⁇ 5° C. until all additions were completed.
- the solution was then allowed to warm to 25° C. and held at that temperature for 14 hr.
- the fluid was purged with N 2 for 2.0 hr to remove excess phosgene, filtered through a layer of MgSO 4 and upon vacuum distillation pure chloroformate was obtained as a clear liquid. Yields were equivalent by these two methods.
- the reaction mixture was slowly warmed to 18° C.-20° C., stirring was continued for 12 hr and 75 mL of water was added.
- the organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 ⁇ 30 mL).
- the combined organic extracts were washed with brine, dried over anhydrous Na 2 SO 4 , and filtered.
- the solvent was removed by rotary vacuum evaporation under reduced pressure to give 38.5 g of a viscous oil, which was held for 1.0 hr under vacuum pump, flushed with nitrogen and weighed.
- the Formyl Reduction method begins with a 4-hydroxybenzaldehyde which, because it possesses only a single hydroxyl, can be unambiguously chloroformylated on the phenolic hydroxyl. Hydride reduction yields the titled product of Step 3A above. However, under basic pH and low temperature conditions p-hydroxybenzyl alcohol can be directly and selectively chloroformylated on its phenolic hydroxyl. This Direct Selective Acylation is discussed as Step 3B.
- Formyl Reduction is carried out in an aqueous slurry of 4.99 g (0.132 moles) NaBH 4 prepared in 25 mL of ice-cold distilled water.
- a solution of 80 mL THF and 11.0 g (0.044 moles) of 4-formylphenyl 3,3-dimethylbutyl carbonate was cooled to ⁇ 8° C.
- the aqueous slurry of sodium borohydride was added slowly to the formyl compound over a period of 30 min. The temperature of the medium rose to 0° C. during addition but continuous stirring for 2 hr in the acetone-ice-salt bath dropped the temperature of the reaction mixture to approximately ⁇ 10 to ⁇ 8° C. The reaction was allowed to gradually warm to 0° C.
- Direct Selective Acylation was effected by first dissolving 0.252 g of 3,3-dimethylbutyl chloroformate (1.0 eq, 1.00 mmol, 158 ⁇ L) in a pre-cooled solution of 0.137 g p-hydroxybenzyl alcohol (also known as 4-hydroxybenzyl alcohol or 4-(hydroxymethyl)phenol) (1.1 eq, 1.10 mmol) in 5 mL of THF under nitrogen atmosphere. Triethylamine (1.0 eq, 1 mmol, 139 ⁇ L) was added over a 20 min period via syringe. Upon precipitation, 3 mL of THF was added to the reaction mixture to ensure efficient stirring. The reaction mixture was slowly warmed up to 18-20° C.
- Step 1 General Procedure for Preparation of Aliphatic Chloroformates with Either Triphosgene or Phosgene
- the reaction mixture was allowed to slowly warm to 18° C.-20° C. with continuous stirring (14 hr). Water (50 mL) was added, the organic layer separated, and the aqueous layer extracted with ethyl acetate (3 ⁇ 25 mL). The combined organic extracts were washed with brine, dried over anhydrous Na 2 SO 4 , filtered, and the solvent was removed by evaporation in vacuo to give 22.2 g of a light yellow viscous oil.
- the crude formyl compound was purified on a silica gel column using 7% ethyl acetate: 93% hexane as eluent. The purified yield was 13.4 g of white crystals (76%).
- Formyl Reduction was effected in an aqueous slurry of 4.26 g (0.113 moles) NaBH 4 prepared in 22 mL of ice-cold distilled water.
- a solution of 70 mL THF and 10.0 g (0.038 moles) of 4-formylphenyl 2-(trimethylsilyl)ethyl carbonate was cooled to ⁇ 8° C.
- the aqueous slurry of sodium borohydride was added slowly to the formyl compound over a period of 30 min. The temperature of the medium rose to 0° C. during addition but continuous stirring for 2 hr in the acetone-ice-salt bath dropped the temperature of the reaction mixture to approximately ⁇ 10 to ⁇ 8° C.
- the reaction was allowed to gradually warm to 0° C. over 2 hr with continuous stirring.
- the reaction mixture was then diluted with 50 mL of saturated NH 4 Cl solution at 18° C., extracted with ether (3 ⁇ 25 mL), and the combined organic extracts were washed with 30 mL of brine solution, dried over anhydrous MgSO 4 , and filtered.
- the solvent was removed by means of a rotary vacuum evaporator to obtain a viscous liquid, which was purified upon passing through silica gel column using hexane:ethyl acetate (4:1) as eluent to give 8.5 (84%) yield of a colorless thick oil.
- Direct Selective Acylation begins with 1.53 g of 2-(trimethylsilyl)ethyl chloroformate (2.6 eq, 8.6 mmol, 1.53 mL) added to a pre-cooled ( ⁇ 5° C.) solution of 0.41 g p-hydroxybenzyl alcohol (1.0 eq, 3.3 mmol) in THF (5 mL) under nitrogen atmosphere. Triethylamine 0.33 g (1.0 eq, 3.3 mmol, 459 ⁇ l) was added to the reaction mixture via syringe over a 20 min period. The reaction mixture was slowly warmed up to 18-20° C. with continuous stirring for 14 hr. Distilled water (5 mL) was added and the organic layer was separated out.
- an appropriate NSAID ibuprofen, naproxen and indomethacin
- Example 11 the NSAID used was (S)-naproxen and the benzyl alcohol was (CH 3 ) 2 CH—CH 2 CH 2 —O—CO—O—C 6 H 4 —CH 2 OH.]
- This target compound was prepared by the same three general steps as discussed under Example 5 above.
- Diclofenac (0.83 mmol, 0.25 g) and 1,1′-carbonyldiimidazole (1.0 mmol, 0.16 g) were combined in dry CH 2 Cl 2 (3 mL) and agitated with a magnetic stirrer for 30 min.
- 4-(Hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate (1.43 mmol, 0.32 g) in CH 2 Cl 2 (2 mL) was added dropwise and the reaction was refluxed at 57° C. for 16 hr.
- Method A and Method B construct the target by synthetic sequences which build the final molecule through the key intermediacy of either a 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate (5) or a 4-(hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate (6).
- the NSAID acid is coupled to the benzylic hydroxyl in an ultimate step as an acid chloride (Method A) or as an in situ activated carboxylic acid (Method B).
- Method C As a third alternative (Method C), one can take advantage of an initial selective esterification of an aliphatic carbinol in the presence of a phenol.
- Step 1 We applied Appendino's general procedure to the selective condensation of the aliphatic hydroxyl in p-hydroxymethylphenol with the carboxyl of 2-(4-isobutylphenyl)propionic acid (ibuprofen) with triphenylphosphine (TPP) and diisopropyl azodicarboxylate (DIAD) in anhydrous tetrahydrofuran (THF)
- ibuprofen 2-(4-isobutylphenyl)propionic acid
- TPP triphenylphosphine
- DIAD diisopropyl azodicarboxylate
- the anhydrous base DBU used in generation of carboxylic acid anions to promote S N 2 reactions on alkyl halides has been shown to extend to NSAIDs (N. Ono, T. Yamada, T. Saito, K. Tanaka, and A. Kaji, Bull. Chem. Soc. Jpn. 1978, 51(8), 2401-2404).
- the appropriate NSAID (4 mmol) was suspended in dry CH 2 Cl 2 (15 mL). Triethylamine (4 mmol, 560 ⁇ L) was then added dropwise followed by 2-chloro-1-methyl-pyridinium iodide (4 mmol, 1.02 g). The mixture was left stirring at room temperature for 6 hr to allow for complete activation of the acid. The lithium salt of N,N-dimethylaminoethanol (4 mmol, 0.40 g) was then added and the resulting mixture was left stirring at room temperature for 2 days. 70 mL CH 2 Cl 2 was added to the reaction mixture and the organic phase was washed with distilled water several times. A substantially pure product was isolated which was carried onto the next step without further purification.
- Methylation was carried out in an appropriate solvent (CH 2 Cl 2 , acetone, THF or diethyl ether) using excess CH 3 I (2 mL). The reaction was left stirring at room temperature overnight. Upon return, if an observable precipitate had not formed, an equal volume of ether was added and the pure product precipitated out of solution. The precipitate was filtered and washed with a small amount of cold ether.
- Acetyl cholinesterase (Type V-S from Electrophorus electricus ), acetyl thiocholine iodide (ACM), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and tacrine hydrochloride were obtained from Sigma-Aldrich (Saint Louis, Mo.). Methanol for the preparation of stock solutions was obtained from EMD Chemicals. Cholinesterase inhibition was assayed spectrophotometrically at 412 nm according to the method of Ellman ( Biochem. Phamacol. 1961, 7: 88-95).
- Assays were performed in polystyrene 96-well plates (Corning 96-well flat transparent) and a conventional micro-plate reader was employed (Tecan's Infinite 200 multimode). The assay procedures were as follow: 200 ⁇ L of 0.5 mM DTNB in 100 mM sodium phosphate buffer (pH 8), 30 ⁇ L of inhibitor stock solution prepared in methanol, 50 ⁇ L of 3 mM AChI and 20 ⁇ L of 1.25 u/mL AChE prepared respectively in phosphate buffer 100 mM pH 8 and 20 mM pH 7. Immediately after the enzyme was added the signal was measured at 30 s intervals over 5 min at 25° C. Percentage inhibition was calculated relative to a control sample (methanol).
- IC 50 values were obtained from a minimum of eight concentrations in duplicate and by fitting the experimental data with a dose-response curve using a curve fitting software (Prism Version 5.00, GraphPad Software, San Diego, Calif.). IC 50 values from 0.51 to 2.29 ⁇ M were measured for the NSAID ester-carbonates of the trimethylsilyl and the t-butyl choline analogs (viz Examples 7-15) and of 77.7 ⁇ M for the true choline species (Example 16).
- the best inhibitor in the NSAID ester-carbonate set has an IC 50 only ten-times higher than that of the clinical standard AChE inhibitor, tacrine hydrochloride.
- the NSAID esters (examples 19-29) inhibited AChE on the micromolar to milimolar scale (see Table 2), they were found less active than their ester-carbonate analog (i.e., the molecules containing the p-functionalized benzyl alcohol, examples 7-18) by at least a factor of 4.
- the most potent NSAID ester (Example 24) inhibited AChE at 2.66 ⁇ M, a value within the range of other known inhibitors.
- the true choline analogues i.e., those with N +
- the true choline analogues i.e., those with N +
- the true choline analogues i.e., those with N +
- the NSAID ester series Examples 27, 28 and 29
- IC 50 values ranging from 0.23 to 3.4 mM.
- Inactivated enzyme was obtained by incubating 20 units of enzyme in 1 mL phosphate buffer (20 mM, pH 7) with 55 ⁇ L of the inhibitor. Stock solution of inhibitors were prepared in methanol and the final concentration of inhibitor was 52 ⁇ M. A control incubation (methanol) was run with the enzyme in absence of the inhibitor. After 30 minutes of incubation at 25° C., an aliquot of 500 ⁇ L was applied to a standardized Sephadex G-25 Medium (PD MiniTrapTM) and eluted with 100 mM sodium phosphate buffer (pH 7) containing 0.1% triton 100 ⁇ in order to maintain enzyme activity. Protein content was assayed using a micro BCA Protein Assay kit (ThermoScientific). Recovery of enzyme activity suggesting reversible inhibition was demonstrated by the Ellman's method previously described (results shown in Table 3).
- a gradient method was run with mobile phase A: 0.1% TFA in water and B: Acetonitrile, method 0 to 2 minutes: 80% A, 2 to 15 minutes: 80% to 15%, 15 to 25: 15%, 25 to 30 minutes: 15% to 80%.
- Authentic standards of the parent pro-drugs, the NSAID, and the 4-hydroxybenzyl alcohol were obtained and used for comparison.
- the release of both the NSAID Naproxen and the 4-hydroxybenzylalcohol suggested both cleavages at the ester and carbonate bond.
- the rate of hydrolysis for pro-drugs was determined at 37° C. in fresh human plasma diluted to 80% with PBS (pH 7.4). Human plasma was obtained from the pooled, heparininised blood of healthy donors and was frozen and stored at ⁇ 80° C. prior to use. Test compounds (20 ⁇ L, 1 mM in DMSO) were added to pre-heated plasma (960 ⁇ L) and mixed gently at 300 rpm. DMSO reached 2% volume content. At suitable intervals, aliquots of 100 ⁇ L were withdrawn and 200 ⁇ L of cold precipitation buffer (90/10 acetonitrile/water with 0.1% formic acid) were added to precipitate proteins from the serum.
- cold precipitation buffer 90/10 acetonitrile/water with 0.1% formic acid
- HPLC method Alignment high resolution XDB-C18 column (1.8 ⁇ m, 4.6 ⁇ 50 mm); mobile phase: water (A) and methanol (B) containing 0.1% formic acid; flow rate: 0.8 mL/min; gradient increase from A/B:70/30 to 30/70 over 8 min, 30/70 to 10/90 over 4 min, 10/90 to 5/95 over 4 min, 5/95 to 70/30 over 4 min, post-time 5 min; injection: 25 ⁇ L; UV detection 230 and 277 nm.
- the mouse ear vesicant model (MEVM) was used to assess the anti-inflammatory activity of dual action therapeutics.
- sulfur mustard or a sulfur mustard analog is applied topically to the ears of female CD-1 mice (24-25 days old) in 20 ⁇ L of dichloromethane or acetone to generate an inflammatory response. This is evident by the appearance of edema in the mouse ears. Edema was measured by increases in the wet weight of ear punch biopsies. Control mice received dichloromethane or acetone without the mustard. To evaluate drugs, ears were pretreated with 20 ⁇ L of vehicle control (dichloromethane or acetone) or 20 ⁇ L of test compounds 20 min prior to treatment with the sulfur mustard.
- the TPA (12-O-tetradecanoylphorbol-13-acetate)-induced ear edema assay was carried out to examine anti-inflammatory activity of dual functional therapeutics in a skin inflammation model.
- the female CD-1 mice 24-25 days old were topically treated with 20 ⁇ l, of acetone or dual functional therapeutic in 20 ⁇ L of acetone at 20 min before topical application of 20 ⁇ L of acetone or TPA (1 nmol) in 20 ⁇ L of acetone. Then, five hr later, all mice were sacrificed and ear punches (6 mm in diameter) were taken and weighed.
- AChE acetylcholine esterase AChI acetylthiocholine iodide CDI 1,1′-carbonyldiimidazole DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCC dicyclohexylcarbodiimide DIAD diisopropyl azodicarboxylate DMAP 4-(dimethylamino)pyridine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- This invention relates to a new class of reversible inhibitors of acetylcholinesterase (International Enzyme classification EC3.1.1.7) which serve simultaneously as pro-drugs capable of releasing non-steroidal anti-inflammatory agents (NSAIDs) by hydrolysis at either one or two chemically different hydrolytically-active loci.
- Inflammatory processes, often amenable to address by non-steroidal anti-inflammatories such as ibuprofen, naproxen, indomethacin and diclofenac, are inherent in the pathologies of multiple sclerosis, Alzheimer's disease, depression, amyotrophic lateral sclerosis, dementia, Parkinson's disease, and other neurodegenerative states. Several of these diseases are also independently characterized by perturbation of cholinergic balance and hence therapies combining cholinesterase inhibitors and inflammation mediators are believe to represent a dual benefit.
- The chronic use of indomethacin and other NSAIDs either in prophylaxis or in therapy risks adverse gastrointestinal effects, renal toxicity, allergic responses, and occasionally severe ulcerations. A highly lipophilic ester “pro-drug” of indomethacin [DP-155] has been claimed to deliver enhanced brain levels while markedly decreasing both renal and gastrointestinal toxicities (E. Dvir, A. Elmann, D. Simmons, I. Shapiro, R. Duvdevani, A. Dahan, A. Hoffman, and J. E. Friedman, CNS Drug Rev. 2007, 13: 260-277). The pro-drug conjugate was efficacious in reducing levels of amyloid ss (Ass) 42 in a transgenic Alzheimer's disease mouse (Tg2576). In DP-155, a methylene chain spacer separated the indomethacin ester from the ester at the lipid carrier terminus. For this purpose, a five carbon spacer was shown to be 20-fold better in transmembrane absorption than a short two-carbon spacer (A. Dahan, R. Duvdevani, E. Dvir, A. Elmann, and A. Hoffman, J. Control Release 2007, 119: 86-93).
- Orally-administered NSAID-esters of basic aminoalcohols are reported to be competitive reversible inhibitors of AChE and to reduce intestinal gastric ulceration often associated with the non-conjugated NSAID carboxylic acids or their salts (P. K. Halen, K. K. Chagti, R. Giridhar, and M. R. Yadav, Chem. Bio. Drug Des. 2007: 70: 450-455). The cholinergic anti-inflammatory pathway is a high value therapeutic target readily justifying the combination of anti-cholinergic and anti-inflammatory activity into a single molecule. Wang has noted that binding at the acetylcholine receptor is a down-regulatory mechanism for inflammation (H. Wang et al., Nature 2003, 421: 384-388).
- Amitai has shown that the combination of an anti-inflammatory (ibuprofen or diclofenac) and an inhibitor of acetylcholinesterase into the same molecule provided a therapeutic benefit in the treatment of inflammation resulting from chemical blistering agents (A. Amitai, R. Adani, E. Fishbein et al., J. Applied Tox., 2006, 26: 81-87). Although doubly functionalized with an NSAID and an anti-cholinergic, in this case the two moieties could not be independently liberated in vivo. Thus there remains a need for additional moieties that can be independently liberated in vivo.
- This application relates to a unique lipophilic pro-drug of an NSAID such as indomethacin (or other NSAIDs) which is simultaneously a competitive reversible inhibitor of acetylcholinesterase and a controlled release carrier of the NSAID. These pharmaceuticals are unsymmetrical alkyl-aryl carbonates whose —O—CO—O— bond is readily cleaved both by chemical hydrolysis and esterolytic activity, thereby freeing an NSAID by a facilitated hydrolysis. Since the NSAID is directly attached to the platform by a hydrolyzable ester function, there are two modes by which the NSAID is made available.
- Accordingly, one embodiment of the invention relates to a compound of Formula 1 wherein
- wherein
- n is 0 or 1;
- X is Si, C, or N+;
- wherein when X is C or N+, each R is alike or different and is hydrogen or (C1-C6) alkyl;
- when X is Si, each R is methyl; and
- NSAID is a non-steroidal anti-inflammatory agent.
- The invention is more fully described below in conjunction with the figures wherein:
-
FIG. 1 shows a HPLC chromatogram obtained in chemical hydrolysis of the compound of Example 9. -
FIG. 2 shows a Lineweaver-Burk plot for reversible inhibition of acetylcholinesterase in absence and in presence of inhibitor Example 9 and 22 wherein the reciprocal of the velocity ν (M min−1) is plotted against the reciprocal of the substrate concentration s (μM). -
FIG. 3 shows a HPLC chromatogram of the hydrolysis of Example 14 and release of parent NSAID after incubation in human plasma. - The high level of esterase activity (arising from native acetylcholinesterases, carboxyesterases, and related esterases) found in human skin, epidermal membranes, and plasma, makes ester-containing pro-drugs attractive targets as drug-delivery vehicles for topical or oral formulations (J. L. Prusakiewicz, C. Ackermann, and R. Voorman, Pharmaceutical Research 2006, 23: 1517-1524). Other studies have shown that a carbonate-linkage (—O—CO—O—) is always very similar in behavior to an ester-linkage as the hydrolysable function joining drug to carrier (J. Rautio et al., Nature Reviews Drug Discovery 2008, 7: 255-270). In a limited set of 17 analogs, Vaddi compared esters to carbonates as pro-drug linkers to naltrexone and found the carbonates to have a faster transdermal flux rate and to be slightly more resistant to hydrolysis in the skin (enzymatic and hydrolytic) itself than was the case with the esters. More esters were cleaved in the skin leaving lower quantities available for penetration and transport in the plasma. The differences in absorption rate and hydrolysis rate between esters and carbonates were real but were not large (H. K. Vaddi, et al. Pharmaceutical Research, 2005, 22: 758-765). As far as purely chemical cleavage, most carbonates were less reactive to hydrolysis in acid or in base than were esters (J. Ostergaard and C. Larsen, Molecules, 2007, 12: 2396-2412).
- The use of the construct p-(X-methyl)phenol (or an ester or carbamate of it) as a platform for the release of two molecular fragments in vivo—both of which in some cases possess biological activity—has been applied by accident and by deliberate design in several agricultural and pharmaceutical products. The principle displayed here is that electron delocalization from the phenolic oxygen provides an indirect cleavage pathway for an anionic species (viz., p-X—CH2—C6H4—O—R if converted by cleavage at R to p-X—CH2—C6H4—O− will liberate X−). The presumed electron pathway is shown below. The attack at R is usually a hydrolysis at a carbonyl.
- In the nitric oxide donating aspirin conjugate known as NO-ASA, R in the structure shown above is aspirin (acetylsalicylic acid) linked at its carboxylic moiety and X is the NO-precursor —O—NO2. Promising results have been reported against colon, pancreatic, and breast cancers as well as in protection of gastric mucosal irritation and enhancement of in situ antioxidant events. (J. L. Williams, P. Ji, N. Ouyang, X. Liu, B. Rigas, Carcinogenesis 2008, 29, 390-397 and S. Kwiecien, M. W. Pawlik, T. Brzozowski, et al, J. Physiol Pharmacol. 2008 Suppl 2:103-15). The in vivo release of thalidomide and nitric oxide from a conjugate drug in which R in the structure above is the carbamate of thalidomide and X is the NO-precursor —O—NO2 arrested the growth of malignant liver cells (T. Wang, Y. H. Zhang, H. Ji, et al., Chinese Chemical Letters, 2008, 19: 26-28). Immonium chlorides derived from DMF and 4-(chloromethyl)phenyl chloroformate (X in above formula=Cl, R═CH═N+Me2) hydrolyzed to useful bactericides presumably by the indicated mechanism but not recognized as such by the authors (V. A. Pattison and R. L. K. Carr, U.S. Pat. No. 3,983,178). In a family of pro-pesticides which hydrolyzed to potent acaricides by the general structure shown above, R═—P(═O)OR/SR′ and X═SCH3. (R. Sehring, W. Buck, R. Prokic-Immel, S. Lust, Ger. Offen. DE 3223949, 1983 and W. Buck, G. Geisthardt, R. Prokic-Immel, R. Sehring, Dokl. Soobshch-Mezhdunar. Kongr. Zashch. Rast., 8th 1975, 3: 50-57).
- As a general class, these substances—with n=0, 1 and X═C, Si, and N+—can be described as:
- Variation in the alkyl function provides the recognition moiety for the target enzyme with choline-like mimics such as —CH2CH2T(Me)3 [wherein T=N+, Si, or C] providing the traditional molecular architecture required for site affinity at acetylcholinesterase. Even though the structural shift from a water-soluble trimethyl ammonium [+NMe3] to a trimethyl carbon [—C(CH3)3] or to a trimethyl silyl [—Si(CH3)3], means an increasing hydrophobicity, these moieties can nevertheless by recognized and bound to acetylcholinesterase. As Cohen phrased it in reference to the quat silyls and quat carbons, . . . “the enzyme stands nearby ready to bind and try to hydrolyze and remove compounds that even superficially resemble the natural agonist.” (S. G. Cohen, S. B. Chishti, J. L. Elkind, H. Reese, and J. B. Cohen, J. Med. Chem. 1985, 28: 1309-1313). Variation of n=1 to n=0 allows the incorporation or non-incorporation of a p-hydroxybenzyl alcohol linker moiety whose presence increases the lipophilicity of the final construct by 1.9 log units (c Log P, a computed quantity for hydropholic/hydrophilic molecular property). In addition to adding lipophilicity when desired, this linker (when present) provides two sites of controlled hydrolytic/enzymatic release of the NSAID at a carbonate and at an ester functionality.
- In an earlier study we disclosed a class of toxic choline-chloromethyl aryl carbonate insecticides which were “suicide-like substrate” inhibitors of acetylcholinesterase. These
-
Cl—CH2—C6H4—O—CO—O—CH2CH2-T(CH3)3 where T=N+ or C - compounds were—upon hydrolysis by the enzyme—covalently and irreversibly linked to AChE. Recent pharmaceutical research, however, has shown that irreversible “suicide inhibition,” which because of the covalent anchoring of the drug fragment generates a now “foreign” protein, can trigger an autoimmune-response in the patient (E. Fontana, P. M. Dansette, and S. M. Poli, Current Drug Metabolism, 2005, 6: 413-454). Thus, too toxic and too inappropriate for human therapeutic use, these substances nevertheless proved useful in control of the tobacco budworm and the southern corn rootworm [N. Heindel, M. Turizo, H. D. Burns, and V. Balasubramanian, U.S. Pat. No. 5,082,964 (Jan. 21, 1992) and N. J. Brenner, N. D. Heindel et al., “Arylcholine Carbonates and Aryl-3,3-dimethyl-1-butyl Carbonates as Inhibitors and Inactivators of Acetylcholinesterase,” Chapter 37 in ACS Symposium #443, Synthesis and Chemistry of Agrochemicals II, ACS Publishers, Washington, D.C., 1991, pp. 469-477].
- Amazingly, we have since discovered that when the leaving group in the above mentioned carbonates is anything other than chloro or bromo, these carbonates are no longer substrates for AChE and they are no longer “suicide-like” irreversible alkylator-inhibitors. Interestingly, Boyle has shown that simple alkyl thiocarbonates of choline are partial competitive inhibitors which are not hydrolyzed by the enzyme (N. A. J. Boyle et al., J. Med. Chem. 1997, 40: 3009-3013). Relatively small changes in these carbonate-choline mimics can have a major effect on activity. That principle has led to the new family of NSAID-ester-carbonates claimed herein as therapeutics for diseases and clinical conditions benefiting from inflammation suppression and cholinergic intervention because an NSAID can be released by two alternative hydrolyses from a highly lipophilic carrier.
- In practice, a composition containing a compound of Formula 1 may be administered in any variety of suitable forms, for example, parenterally, rectally, or orally. More specific routes of administration include intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, colonical, peritoneal, transepithelial including transdermal, ophthalmic, sublingual, buccal, dermal, ocular, nasal inhalation via insufflation, and aerosol.
- A composition containing a compound of Formula 1 may be presented in forms permitting administration by the most suitable route. The invention also relates to administering compositions containing a compound of Formula 1 which is suitable for use as a medicament in a patient. These compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of oral dosage forms, or injectable solutions, or suspensions.
- The choice of vehicle and the compound of Formula 1 in the vehicle are generally determined in accordance with the solubility and chemical properties of the product, the particular mode of administration and the provisions to be observed in pharmaceutical practice. When aqueous suspensions are used they may contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyols such as polyethylene glycol, propylene glycol and glycerol, and chloroform or mixtures thereof may also be used. In addition, the compound of Formula 1 may be incorporated into sustained-release preparations and formulations.
- For parenteral administration, emulsions, suspensions or solutions of the compounds according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts (when X is N+), are used. The injectable forms must be fluid to the extent that it can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size, in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. Solutions of the neutral compound of Formula 1 wherein X is C or Si and pharmacologically acceptable salts of the subgenus of Formula 1 wherein X is N+ can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation, microfiltration, and/or by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating the compound of Formula 1 in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique, which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- Topical administration, gels (water or alcohol based), creams or ointments containing the compound of Formula 1 may be used. The compound of Formula 1 may be also incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through transdermal barrier.
- The percentage of compound of Formula 1 in the compositions used in the present invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. A dose employed may be determined by a physician or qualified medical professional, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 10, mg/kg body weight per day by intravenous administration. In each particular case, the doses are determined in accordance with the factors distinctive to the patient to be treated, such as age, weight, general state of health and other characteristics, which can influence the efficacy of the compound according to the invention.
- The compound of Formula 1 used in the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the compound of Formula 1 may be administered 1 to 4 times per day. Of course, for other patients, it will be necessary to prescribe not more than one or two doses per day.
- Synthetic assembly of the NSAID-cholinergic conjugate was achieved by four different experimental techniques. First, in METHOD A, an acid chloride of the NSAID can be coupled to the appropriate p-hydroxymethylphenyl carbonate. NSAIDs used in this work were naproxen, ibuprofen, indomethacin, and diclofenac, but the method is general to the release of any other carboxyl terminated anti-inflammatory or other carboxyl-containing pharmaceuticals. As a specific example, the coupling of ibuprofen acid chloride to 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate is shown. Syntheses of the acid chlorides and the 4-(hydroxymethyl)phenyl carbonates as required in METHOD A is described below.
- The compounds are administered to patients by means known in the art including orally, parentally. The compounds of the invention are formulated as liquids, suspensions, tablets as is known in the art.
- All reactants and solvents were of the highest purity commercial grade and were employed without further purification. The suppliers of uncommon reactants are indicated for those reactions and assays reported herein which employ a specialized reagent. All reactions were performed in oven-dried apparatus. 1H NMR and 13C NMR, spectra were recorded on a 500 MHz (Bruker) multinuclear spectrometer and chemical shifts are reported as ppm. All thin layer chromatography (TLC) was performed on Analtech silica gel plates (250 microns). Elemental analyses were performed at Quantitative Technologies (QTI), Inc. The 2-(2-methoxynaphthalene-6-yl)propanoic acid (naproxen) used in this work was the (S)-enantiomer. All other reagents were used as racemates.
- By METHOD A, an NSAID converted to its acid chloride is coupled to 4-hydroxybenzaldehyde, the aldehyde reduced to a benzyl alcohol, and that alcohol condensed with an appropriate chloroformate (which had been prepared in a separate synthetic step) to give the objects of this invention, the final carbonate-esters, in overall yields of 22-45% for this five-step pathway. This variation of METHOD A is the Formyl Reduction Pathway.
- An abbreviated variation of METHOD A, the Direct Selective Acylation Pathway, uses pH and temperature control to condense the chloroformate specifically onto the phenolic —OH of p-hydroxybenzyl alcohol. This variation avoids the use of p-hydroxybenzaldehyde and shortens the synthesis by one step. This boosts the overall yields to 35-55%. Both pathways are discussed with specific examples below.
-
- A silicone oil bath was heated to 130° C. A reaction set-up was prepared consisting of a 200 mL round bottom flask with condenser and rubber septum-capped joints. After mixing the reactants as described below, the flask and contents were placed in the oil bath. Thionyl chloride (29.7 g, 0.25 mol) was added via glass syringe to 2-(4-isobutylphenyl)propionic acid (10.3 g, 0.05 mol) in dry toluene (60 mL) at room temperature under nitrogen atmosphere. The reaction mixture was then heated at 130° C. for 2.5 hr, removed from the oil bath, and allowed to cool to room temperature. The condenser walls were rinsed with 10 mL of toluene and the washing was added to the reaction mixture. The toluene and excess thionyl chloride were removed under reduced pressure and the light yellow liquid was held under vacuum pump for 45 min. This pale yellow-colored oil weighed (9.98 g) and represented a yield of 62% as calculated from 1H NMR. This ibuprofen acid chloride was used directly for next reaction without further purification.
- Light Yellow Liquid; 62% yield, Rf=0.62 (30% ethyl acetate: 70% hexane).
- 1H NMR (CDCl3) δ 0.99 (d, 6H, J=6.64 Hz, 2×Me), 1.62 (d, 3H, J=7.06 Hz, Me), 1.95 (m, 1H, CH), 2.54 (d, 2H, J=7.19 Hz, CH2), 4.15 (q, 1H, J=7.05, CH), 7.22 (d, 2H, J=8.12 Hz, ArH), 7.27 (d, 2H, J=8.12 Hz, ArH).
- 13C NMR (CDCl3) δ 18.49, 22.21, 29.99, 44.84, 56.94, 127.50, 129.61, 134.56, 141.54, 175.30.
-
- By the method and equipment described in Example 2, 25.8 g (0.22 mol) of thionyl chloride was added via glass syringe to 10.0 g (0.043 mol) of (S)-2-(2-methoxynaphthalene-6-yl)propanoic acid (also known as naproxen) in 60 mL of dry toluene at room temperature under nitrogen atmosphere. The reaction mixture was then heated at 130° C. for 2.5 hr and worked up as described. Evaporation in vacuo began to precipitate a light yellow solid to which 40 mL of anhydrous hexane were added. The hexane and the suspended yellow solid were stirred vigorously under dry nitrogen atmosphere for 10 min and filtered to obtain, after vacuum drying, 9.85 g of light yellow acid chloride. Dry hexane was added (40 mL), and stirred for 10 min. under nitrogen. This crude product was stored in a nitrogen flushed glass vial and used for the coupling reaction without additional purification. The yield of 79%, from naproxen to the acid chloride, was determined by 1H NMR by integrating peak areas of residual starting material and product.
- Light Yellow solid; 79% yield, Rf=0.39 (30% ethyl acetate: 70% hexane).
- 1H NMR (CDCl3) δ 1.68 (d, 3H, J=6.91 Hz, Me), 3.91 (s, 3H, OCH3), 4.24 (q, 1H, J=6.84 Hz, CH), 7.15 (brd, 2H, ArH), 7.19 (d, 1H, J=8.58 Hz, ArH), 7.69 (brd, 2H, ArH), 7.71 (d, 1H, J=8.8 Hz, ArH).
- 13C NMR (CDCl3) δ 18.63, 55.27, 57.33, 105.56, 118.98, 125.26, 126.14, 127.19, 128.84, 129.25, 132.42, 134.80, 157.69, 175.63.
-
- With the apparatus as described in Example 2, a solution of 10.0 g (0.028 mol) of 2-[1-(4′-chlorobenzoyl)-2-methyl-5-methoxy-1H-indol-3-yl)]acetic acid (indomethacin), 50 mL of dry methylene chloride, and 0.50 mL anhydrous DMF was prepared under a blanket of dry nitrogen gas. Oxalyl chloride (5.32 g, 0.042 mol) was added drop wise to this solution at ambient temperature over 30 min. This reaction was not heated in the silicone oil, but was stirred gently at room temperature for 8 hr. The solvent and excess oxalyl chloride were removed under vacuum while insuring that the temperature of the contents remained below 40° C. The solid obtained was slurried with 30 mL of dry hexane, stirred for 10 min and filtered. The pale gray solid indomethacin acid chloride (9.78 g) was dried under vacuum for 1.0 hr and was used for the next reaction without additional purification. The yield as determined by integration of product and starting material peaks in the 1H NMR was 92%. Product was a light gray solid, Rf=0.32 (5% methanol: 95% methylene chloride)
- 1H NMR (CDCl3) δ 2.40 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 4.16 (s, 2H, CH2), 6.69 (dd, 1H, J=2.43, 8.96 Hz, ArH), 6.85 (m, 2H, ArH), 7.47 (d, 2H, J=8.43 Hz, Ar), 7.66 (d, 2H, J=8.33 Hz, ArH).
- 13C NMR (CDCl3): δ 13.30, 42.34, 55.75, 100.90, 109.98, 112.11, 115.07, 129.13, 129.22, 129.76, 130.79, 131.17, 131.25, 133.51, 137.12, 139.65, 156.27, 168.23, 170.95.
-
- Three discrete steps are required to prepare these unsymmetrical aliphatic-aromatic carbonates. The preparation commences with the synthesis of an aliphatic chloroformate [R—O—CO—Cl], followed by its coupling to 4-hydroxybenzaldehyde, and finally concludes with the subsequent reduction of the aldehyde function. The specific route to both 4-(hydroxymethyl)phenyl carbonates is described.
-
- Triphosgene (0.75 moles) dissolved in 200 mL of anhydrous CH2Cl2 was cooled to 0° C. and 1.0 moles of the corresponding aliphatic alcohol [X═C or Si] were added drop wise under nitrogen with stirring in a 500 mL round bottom fitted with condenser and pressure equalized side-arm dropping funnel. Then 1.20 moles of triethylamine in 50 mL of anhydrous methylene chloride were added drop wise while maintaining the reaction temperature below 4° C. When addition was complete, the solution was allowed to warm to 25° C. and the fluid was stirred for 16 hr. Anhydrous nitrogen gas was vigorously bubbled through the solution for 1 hr to purge it of excess triphosgene. The fluid contents were then poured into water, the organic layer was separated (caution: pressure develops in the separatory funnel), and the organics were dried over anhydrous MgSO4. After evaporation of the solvents in vacuo, a vacuum distillation yielded pure chloroformate as clear liquid in a 75-85% yield.
- Although somewhat more difficult to handle and more hazardous, the same reaction can be carried out with phosgene gas (1.2 molar equivalents as a 20 wt % solution of phosgene in toluene). The phosgene-toluene was first cooled to −8° C. to −10° C. and then the aliphatic alcohols (1.0 molar equivalents in methylene chloride) are added drop wise followed by 1.2 molar equivalents of triethylamine. The reaction temperature was held at or below −5° C. until all additions were completed. The solution was then allowed to warm to 25° C. and held at that temperature for 14 hr. The fluid was purged with N2 for 2.0 hr to remove excess phosgene, filtered through a layer of MgSO4 and upon vacuum distillation pure chloroformate was obtained as a clear liquid. Yields were equivalent by these two methods.
- [In Step 1 for Example 11, below, 3-methylbutanol was the corresponding aliphatic alcohol employed to generate the chloroformate (CH3)2CH—CH2CH2—O—CO—Cl].
-
- Freshly prepared 3,3-dimethylbutyl chloroformate (24.3 g, 0.147 moles) was added to a solution of 4-hydroxybenzaldehyde (15.0 g, 0.123 moles) in 100 mL THF in a round-bottom flask which had been pre-chilled to −5° C. in an acetone-ice-salt mixture under nitrogen atmosphere. Triethylamine (14.9 g, 0.147 moles) was added to the reaction mixture via syringe over a period of 20 min. Precipitation was observed almost instantly and an additional 30 mL of THF were added for more efficient stirring. The reaction mixture was slowly warmed to 18° C.-20° C., stirring was continued for 12 hr and 75 mL of water was added. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3×30 mL). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, and filtered. The solvent was removed by rotary vacuum evaporation under reduced pressure to give 38.5 g of a viscous oil, which was held for 1.0 hr under vacuum pump, flushed with nitrogen and weighed. TLC on silica plates with 18% ethyl acetate: 82% hexane as the mobile phase showed a product spot at Rf 0.57, a small amount of unreacted 4-hydroxybenzaldehyde at Rf 0.25 and a trace of a byproduct at Rf 0.05. Pure 4-formylphenyl 3,3-dimethylbutyl carbonate (26.6 g, 86% yield) could be obtained by column chromatography of the crude oil on a silica column with 12% ethyl acetate: 88% hexane as the mobile phase. White needle-like crystals of product were obtained which could readily be recrystallized from ether:hexane to high purity. The yield in next step reduction reaction has been evaluated on both the crude formyl and on the chromatographically purified formyl. Purification of the formyl precursor does not affect the yield of 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate. White needles (ether-hexane), mp 214-216° C., Rf=0.57 (18% ethyl acetate: 82% hexane)
- 1H NMR (CDCl3) δ 0.96 (s, 9H, 3×Me), 1.68 (t, 2H, J=7.40 Hz, CH2), 4.32 (t, 2H, J=7.36 Hz, CH2), 7.28 (d, 2H, J=6.90 Hz, ArH), 8.13 (d, 2H, J=6.90 Hz, ArH), 9.98 (s, 1H, CHO).
- 13C NMR (CDCl3) δ 29.52, 29.67, 41.60, 67.02, 121.14, 126.89, 131.92, 152.93, 155.34, 171.33. Anal. calcd for C14H18O4 H2O; C, 62.67; H, 7.51. Found: C, 62.80; H, 6.76.
- [In Step 2 for Example 11 3-methylbutyl chloroformate was the chloroformate used to generate the target aldehyde, (CH3)2CH—CH2CH2—O—CO—O—C6H4—CHO-p].
-
- There are two different experimental methods which produce the hydroxymethylphenol carbonates: 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate and 4-(hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate. The Formyl Reduction method begins with a 4-hydroxybenzaldehyde which, because it possesses only a single hydroxyl, can be unambiguously chloroformylated on the phenolic hydroxyl. Hydride reduction yields the titled product of Step 3A above. However, under basic pH and low temperature conditions p-hydroxybenzyl alcohol can be directly and selectively chloroformylated on its phenolic hydroxyl. This Direct Selective Acylation is discussed as Step 3B.
- Formyl Reduction is carried out in an aqueous slurry of 4.99 g (0.132 moles) NaBH4 prepared in 25 mL of ice-cold distilled water. A solution of 80 mL THF and 11.0 g (0.044 moles) of 4-formylphenyl 3,3-dimethylbutyl carbonate was cooled to −8° C. The aqueous slurry of sodium borohydride was added slowly to the formyl compound over a period of 30 min. The temperature of the medium rose to 0° C. during addition but continuous stirring for 2 hr in the acetone-ice-salt bath dropped the temperature of the reaction mixture to approximately −10 to −8° C. The reaction was allowed to gradually warm to 0° C. over 2.5 hr with continuous stirring. The reaction mixture was then diluted with 50 mL of saturated aqueous NH4Cl solution at 18° C., extracted with ether (3×25 mL), and the combined organic extracts were washed with 30 mL of brine solution, dried over anhydrous MgSO4, and filtered. The solvent was removed by means of a rotary vacuum evaporator to obtain a viscous liquid, which was purified upon passing through silica gel column using hexane:ethyl acetate (4:1) as eluent to give 10.2 g of white microcrystals.
- White solid, 91% yield, mp 62-63° C. (recrystallized from ether-hexane), Rf=0.24 (20% ethyl acetate: 80% hexane).
- 1H NMR (CDCl3) δ 0.94 (s, 9H, 3×Me), 1.66 (t, 2H, J=7.63 Hz, CH2), 1.84 (s, 1H, OH), 4.28 (t, 2H, J=7.54 Hz, CH2), 4.64 (d, 2H, J=5.91 Hz, CH2), 7.13 (d, 2H, J=8.54 Hz, ArH), 7.34 (d, 2H, J=8.56 Hz, ArH).
- 13C NMR (CDCl3) δ 29.52, 29.65, 41.63, 64.63, 66.67, 121.14, 128.01, 138.64, 150.53, 153.74. Anal. calcd. for C14H20O4: C, 66.65; H, 7.99. Found: C, 66.29; H, 7.82.
- [In Step 3 for Example 11 (CH3)2CH—CH2CH2—O—CO—O—C6H4—CHO-p was the precursor of the para-substituted benzyl alcohol, (CH3)2CH—CH2CH2—O—CO—O—C6H4—CH2OH].
-
- Direct Selective Acylation was effected by first dissolving 0.252 g of 3,3-dimethylbutyl chloroformate (1.0 eq, 1.00 mmol, 158 μL) in a pre-cooled solution of 0.137 g p-hydroxybenzyl alcohol (also known as 4-hydroxybenzyl alcohol or 4-(hydroxymethyl)phenol) (1.1 eq, 1.10 mmol) in 5 mL of THF under nitrogen atmosphere. Triethylamine (1.0 eq, 1 mmol, 139 μL) was added over a 20 min period via syringe. Upon precipitation, 3 mL of THF was added to the reaction mixture to ensure efficient stirring. The reaction mixture was slowly warmed up to 18-20° C. and kept stirring for 12 hr. Distilled water (8 mL) was added and the organic layer was separated from the aqueous layer. The aqueous layer was then extracted with ethyl acetate (3×15 mL). The combined organic extracts were washed with brine and dried over anhydrous magnesium sulfate. The solvent was removed by rotary evaporation under reduced pressure, resulting in a clear, viscous oil (0.22 g, 87%). The crude product was purified upon passing through a silica gel column using 99% methylene chloride: 1% methanol as eluent to give a pure, clear liquid (0.14 g, 56%). The product was chromatographically and spectrally identical with that prepared by Formyl Reduction in Step 3A above.
- Following the procedure described under Example 5, Step 1, with 2-(trimethylsilyl)ethanol and triphosgene, a 75% yield of 2-(trimethylsilyl)ethyl chloroformate was obtained which was used without purification in Step 2 below.
-
- Into a 250 mL three-neck round bottom flask fitted with a condenser, rubber serum-capped joint, and gas bubbler was charged a solution of 4-hydroxybenzaldehyde (8.0 g, 0.066 mol) in THF (70 mL). This solution maintained under nitrogen atmosphere was pre-cooled to −5° C. in an acetone-ice-salt slurry and 2-(trimethylsilyl)ethyl chloroformate (15.4 g, 0.085 mol) was added. Subsequently, triethylamine (8.68 g, 0.085 mol) was added drop wise to the reaction mixture via syringe over a period of 20 min. The reaction mixture was allowed to slowly warm to 18° C.-20° C. with continuous stirring (14 hr). Water (50 mL) was added, the organic layer separated, and the aqueous layer extracted with ethyl acetate (3×25 mL). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered, and the solvent was removed by evaporation in vacuo to give 22.2 g of a light yellow viscous oil. The crude formyl compound was purified on a silica gel column using 7% ethyl acetate: 93% hexane as eluent. The purified yield was 13.4 g of white crystals (76%).
- Yield of 76%, mp 194-196° C. after recrystallization from ether-hexane, Rf=0.63 (15% ethyl acetate: 85% hexane).
- 1H NMR (CDCl3) δ 0.07 (s, 9H, 3×Me), 1.14 (t, 2H, J=8.6 Hz, CH2), 4.36 (t, 2H, J=8.5 Hz, CH2), 4.65 (s, 2H, CH2), 7.13 (d, 2H, J=8.4 Hz, Ar), 7.28 (d, 2H, J=8.4 Hz, ArH).
- 13C NMR (CDCl3) δ −1.55, 17.55, 67.92, 121.19, 126.82, 131.92, 152.90, 155.39, 170.91. Anal. calcd. for C13H18O4Si, 0.25; H2O, C, 57.62; H, 6.88. Found: C, 57.54; H, 6.70.
-
- Formyl Reduction was effected in an aqueous slurry of 4.26 g (0.113 moles) NaBH4 prepared in 22 mL of ice-cold distilled water. A solution of 70 mL THF and 10.0 g (0.038 moles) of 4-formylphenyl 2-(trimethylsilyl)ethyl carbonate was cooled to −8° C. The aqueous slurry of sodium borohydride was added slowly to the formyl compound over a period of 30 min. The temperature of the medium rose to 0° C. during addition but continuous stirring for 2 hr in the acetone-ice-salt bath dropped the temperature of the reaction mixture to approximately −10 to −8° C. The reaction was allowed to gradually warm to 0° C. over 2 hr with continuous stirring. The reaction mixture was then diluted with 50 mL of saturated NH4Cl solution at 18° C., extracted with ether (3×25 mL), and the combined organic extracts were washed with 30 mL of brine solution, dried over anhydrous MgSO4, and filtered. The solvent was removed by means of a rotary vacuum evaporator to obtain a viscous liquid, which was purified upon passing through silica gel column using hexane:ethyl acetate (4:1) as eluent to give 8.5 (84%) yield of a colorless thick oil.
- Colorless oil, Rf=0.25 (82% hexane:18% ethyl acetate).
- 1H NMR (CDCl3) δ 0.05 (s, 9H, 3×Me), 1.11 (t, 2H, J=6.71 Hz, CH2), 2.29 (brs, 1H, OH), 4.33 (t, 2H, J=7.30 Hz, CH2), 4.65 (s, 2H, CH2), 7.13 (d, 2H, J=8.85 Hz, Ar), 7.32 (d, 2H, J=8.70 Hz, ArH).
- 13C NMR (CDCl3) δ −1.61, 17.46, 64.47, 67.36, 121.10, 127.96, 138.59, 150.43, 153.70. Anal. calcd. for C13H20O4Si: C, 58.18; H, 7.51. Found: C, 57.74; H, 7.49.
-
- Direct Selective Acylation begins with 1.53 g of 2-(trimethylsilyl)ethyl chloroformate (2.6 eq, 8.6 mmol, 1.53 mL) added to a pre-cooled (−5° C.) solution of 0.41 g p-hydroxybenzyl alcohol (1.0 eq, 3.3 mmol) in THF (5 mL) under nitrogen atmosphere. Triethylamine 0.33 g (1.0 eq, 3.3 mmol, 459 μl) was added to the reaction mixture via syringe over a 20 min period. The reaction mixture was slowly warmed up to 18-20° C. with continuous stirring for 14 hr. Distilled water (5 mL) was added and the organic layer was separated out. The aqueous layer was then extracted with ethyl acetate (3×15 mL) and the combined organic extracts were washed with brine and dried over anhydrous magnesium sulfate. Ethyl acetate was removed by rotary evaporation under reduced pressure, resulting in light yellow oil (0.62 g, 70%). The product was chromatographically and spectrally identical to that prepared by Formyl Reduction described in Step 3A above.
- General Procedure for Synthesis of the NSAID Carbonates Containing the p-Hydroxybenzyl Alcohol Linker, n=1 in Formula 1 [Method A]
- A reaction mixture containing 1.2 mmol of either 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate or 4-(hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate and 1.3 mmol of acid chloride of an appropriate NSAID (ibuprofen, naproxen and indomethacin) in 20 mL of anhydrous THF was chilled to −5° C. in an ice-salt bath. Triethylamine (4 mmol) was added drop wise over 20 min, holding the temperature below −5° C. Triethylammonium chloride precipitated. The reaction mixture was stirred below −5° C. for an additional 1.0 hr and then gradually allowed to warm to 18° C. with continuous stirring for 7-12 hr, or until all the NSAID acid chloride had been consumed (as determined by TLC). Water (30 mL) was added to the reaction mixture, and the resulting fluid was extracted with ethyl acetate (3×30 mL). The combined organic phase was washed with brine, dried and concentrated under reduced pressure. The crude products were purified on a silica gel column chromatography using 10% ethyl acetate-90% hexane as eluent. As an identification marker each product was characterized by its Rf on silica gel TLC with an optimized mixed solvent mobile phase. Melting points are reported for those compounds which crystallized. The yields, TLC, combustion analyses, and NMR spectra are reported with each example. [In Example 11 the NSAID used was (S)-naproxen and the benzyl alcohol was (CH3)2CH—CH2CH2—O—CO—O—C6H4—CH2OH.]
- By the above general method the titled compound was prepared in 48% yield.
- Colorless oil, 48% yield, Rf=0.43 (90% hexane: 10% ethyl acetate)
- 1H NMR (CDCl3) δ 0.92 (d, J=6.60 Hz, 6H, 2×Me), 0.99 (s, 9H, 3×Me), 1:51 (d, J=7.17 Hz, 3H, Me), 1.69 (t, J=7.47 Hz, 2H, CH2), 1.86 (m, 1H, CH), 2.46 (d, J=7.17 Hz, 2H, CH2), 3.75 (q, J=7.13, 1H, CH), 4.32 (t, J=7.65 Hz, 2H, CH2), 5.09 (s, 2H, CH2), 7.09 (d, 2H, J=7.96 Hz, ArH), 7.11 (d, 2H, J=8.43 Hz, Ar), 7.19 (d, 2H, J=8.12 Hz, ArH), 7.22 (d, 2H, J=8.86 Hz, ArH).
- 13C NMR (CDCl3) δ 18.23, 22.24, 29.41, 29.51, 30.03, 41.51, 44.89, 44.96, 65.35, 66.47, 120.91, 127.07, 128.82, 129.19, 133.72, 137.43, 140.39, 150.70, 153.45, 174.16. Anal. Calcd. for (C27H36O5 0.5H2O): C, 72.11; H, 8.28. Found: C, 72.22; H, 8.08.
- By the above general method the titled compound was prepared in 56% yield.
- Colorless oil, 56% yield, Rf=0.62 (85% hexane: 15% ethyl acetate).
- 1H NMR (CDCl3) δ 0.09 (s, 9H, 3×Me), 0.91 (d, 6H, J=6.65 Hz, 2×Me), 1.14 (t, 2H, J=7.85 Hz, CH2), 1.51 (d, 3H, J=7.15 Hz, CH3), 1.86 (m, 1H, CH), 2.46 (d, 2H, J=7.15 Hz, CH2), 3.74 (q, 1H, J=7.15 Hz, CH), 4.35 (t, 2H, J=8.75 Hz, CH2), 5.08 (s, 2H, CH2), 7.09 (d, 2H, J=7.95 Hz, ArH), 7.11 (d, 2H, J=8.5 Hz, Ar), 7.19 (d, 2H, J=8.05 Hz, ArH), 7.23 (d, 2H, J=8.60 Hz, ArH).
- 13C NMR (CDCl3) δ −1.60, 17.47, 18.30, 22.31, 30.11, 44.97, 45.05, 65.49, 67.34, 121.04, 127.14, 128.92, 129.27, 133.75, 137.49, 140.52, 150.80, 153.51, 174.32. Anal. calcd. for C26H36O5Si: C, 68.39; H, 7.95. Found: C, 68.37; H, 7.94.
-
- White solid, 62% yield, mp 63-64° C., Rf=0.44 (80% hexane: 20% ethyl acetate).
- 1H NMR (CDCl3) δ 0.96 (s, 9H, 3×Me), 1.57 (d, 3H, J=7.16 Hz, Me), 1.67 (t, 2H, J=7.59 Hz, CH2), 3.89 (q, 1H, J=7.14 Hz, CH), 3.94 (s, 3H, OMe), 4.29 (t, 2H, J=7.48 Hz, CH2), 5.08 (q, 2H, J=12.55 Hz, CH2), 7.08 (brd, 2H, J=8.52 Hz, ArH), 7.10 (d, 1H, J=2.41 Hz, Ar), 7.13 (dd, 1H, J=2.52, 8.87 Hz, Ar), 7.23 (brd, 2H, J=8.49 Hz, ArH), 7.37 (dd, 1H, J=1.79, 8.5 Hz, ArH), 7.63 (brs, 1H, ArH), 7.67 (d, 1H, J=8.77 Hz, ArH), 7.68 (d, 1H, J=8.39 Hz, ArH).
- 13C NMR (CDCl3) δ 18.44, 29.53, 29.66, 41.65, 45.44, 55.28, 65.70, 66.68, 105.64, 118.97, 121.09, 125.97, 126.21, 127.15, 128.93, 129.13, 129.27, 133.72, 133.76, 135.46, 150.89, 153.58, 157.68, 174.32. Anal. calcd. for C28H32O6: C, 72.39; H, 6.94. Found: C, 72.37; H, 7.13.
-
- White solid, 64% yield, mp 58-59° C., Rf=0.49 (80% hexane: 20% ethyl acetate).
- 1H NMR (CDCl3) δ 0.06 (s, 9H, 3×Me), 1.12 (t, 2H, J=8.70 Hz, CH2), 1.56 (d, 3H, J=7.16 Hz, CH3), 3.87 (q, 1H, J=7.16 Hz, CH), 3.90 (s, 3H, OMe), 4.32 (t, 2H, J=8.68 Hz, CH2), 5.08 (q, 2H, J=12.54 Hz, CH2), 7.07 (brd, 2H, J=8.52 Hz, ArH), 7.10 (d, 1H, J=2.39 Hz, Ar), 7.12 (dd, 1H, J=2.51, 8.88 Hz, ArH), 7.22 (brd, 2H, J=8.44 Hz, ArH), 7.37 (dd, 1H, J=1.78, 8.50 Hz, ArH), 7.62 (brs, 1H, ArH), 7.66 (d, 1H, J=8.78 Hz, ArH), 7.68 (d, 1H, J=8.40 Hz, ArH)
- 13C NMR (CDCl3) δ −1.55, 17.54, 18.45, 45.46, 55.30, 65.73, 67.42, 105.66, 118.98, 121.13, 125.98, 126.22, 127.16, 128.94, 129.14, 129.28, 133.72, 135.48, 150.92, 153.55, 157.69, 174.33. Anal. calcd. for C27H32O6Si: C, 67.47; H, 6.71. Found: C, 67.91; H, 7.03
- This target compound was prepared by the same three general steps as discussed under Example 5 above.
-
- From 3-methylbutyl chloroformate and p-hydroxybenzaldehyde following the general method described under Example 5 this aldehyde carbonate was obtained in 67% yield as a viscous oil.
- 1H NMR (CDCl3) δ 0.96 (d, 6H, J=7.41 Hz, 2×Me), 1.71 (m, H, J=7.40 Hz, J=7.38, CH), 1.62 (m, 2H, J=7.38 Hz, CH2), 4.29 (t, 2H, J=7.38 Hz, CH2), 7.34 (d, 2H, J=6.90 Hz, ArH), 7.90 (d, 2H, J=6.90 Hz, ArH), and 9.97 ppm (s, 1H, CHO).
- 13C NMR (CDCl3) δ 22.38, 24.81, 38.17, 67.95, 121.7, 131.2, 134.1, 152.9, 155.6, 190.7.
-
- Following the general method described in Step 3 under Example 5 this target benzyl alcohol was obtained in 77% yield.
- 1H NMR (CDCl3) δ 0.95 (d, 6H, J=7.40 Hz, 2×Me), 1.74 (m, H, J=7.40 Hz, J=7.38, CH), 1.63 (m, 2H, J=7.38 Hz, CH2), 4.25 (m, two overlapping methylenes, 4H, two CH2), 4.65 (s, 1H, OH), 7.14 (d, 2H, J=6.80 Hz, ArH), and 7.34 ppm (d, 2H, J=6.80 Hz, ArH).
-
- This 4-(hydroxymethyl)phenyl 3-methylbutyl carbonate, prepared in Step 3 (above) was reacted with (S)-naproxen acid chloride as described in the General Procedure for Synthesis of the NSAID Carbonates [Method A]. A 29% yield of Example 11 was prepared as a clear oil.
- 1H NMR (CDCl3) δ 0.96 (d, 6H, J=7.40 Hz, 2×Me), 1.57 (d, 3H, J=7.16 Hz, Me), 2.00 (m, 2H, CH2), 3.95 (two overlapping and m, 2H, J=7.14 Hz, two CH), 3.98 (s, 3H, OMe), 4.59 (t, 2H, J=7.48 Hz, CH2), 5.08 (q, 2H, J=12.6 Hz, benzylic CH2), 7.08 to 7.89 (m, 10H, ArH).
-
- Yellow liquid, 55% yield, Rf=0.5 (75% hexane: 25% ethyl acetate)
- 1H NMR (CDCl3) δ 0.96 (s, 9H, 3×Me), 1.67 (t, 2H, J=7.56 Hz, CH2), 2.33 (s, 3H, CH3), 3.67 (s, 2H, CH2), 3.72 (s, 3H, OMe), 4.29 (t, 2H, J=7.46 Hz, OCH2), 5.09 (s, 2H, OCH2), 6.64 (dd, 1H, J=2.52, 9.01 Hz, ArH), 6.87 (d, 1H, J=9.0 Hz, ArH), 6.92 (d, 1H, J=2.48 Hz, ArH), 7.11 (dd, 2H, J=1.9, 6.59 Hz, ArH), 7.27 (d, 2H, J=8.59 Hz, ArH), 7.41 (dd, J=1.82, 6.70 Hz, 2H, ArH), 7.60 (dd, 2H, J=1.87, 6.64 Hz, ArH).
- 13C NMR (CDCl3) δ 13.09, 29.32, 29.42, 30.09, 41.42, 55.33, 65.71, 66.44, 101.04, 111.58, 112.18, 114.73, 120.94, 128.84, 129.10, 130.32, 130.58, 130.91, 133.32, 133.73, 135.63, 138.87, 150.81, 153.30, 155.86, 167.88, 170.22.
- Anal. calcd. for C33H34ClNO7: C, 66.94; H, 5.79; N, 2.37. Found C, 66.64; H, 5.97; N, 2.42.
-
- Yellow liquid, 59% yield, Rf=0.55 (75% hexane: 25% ethyl acetate).
- 1H NMR (CDCl3) δ 0.07 (s, 9H, 3×Me), 1.13 (t, 2H, J=8.66 Hz, CH2), 2.35 (s, 3H, CH3), 3.69 (s, 2H, CH2), 3.75 (s, 3H, OMe), 4.34 (t, 2H, J=8.65 Hz, CH2), 5.10 (s, 2H, CH2), 6.65 (dd, 1H, J=2.53, 9.0 Hz, ArH), 6.87 (d, 1H, J=9.03 Hz, ArH), 6.91 (d, 1H, J=2.49 Hz, ArH), 7.12 (dd, 2H, J=1.91, 8.58 Hz, ArH), 7.29 (d, 2H, J=8.57 Hz, ArH), 7.44 (dd, 2H, J=1.84, 8.86 Hz, ArH), 7.63 (dd, 2H, J=1.89, 8.89 Hz, ArH).
- 13C NMR (CDCl3) δ −1.62, 13.25, 17.45, 30.29, 55.55, 65.93, 67.38, 101.17, 111.75, 112.31, 114.88, 121.15, 129.02, 129.28, 130.46, 130.73, 131.07, 133.38, 133.85, 135.84, 139.13, 150.99, 153.44, 156.00, 168.14, 170.44.
- Anal. calcd. for C32H34ClNO7Si: C, 63.20; H, 5.64; N, 2.30. Found: C, 63.06; H, 5.67; N, 2.30.
- These 4-(hydroxymethyl)phenyl carbonates [5, 6, and 5 desmethyl] of the two types shown below can also be coupled to the NSAID carboxylic acids without first converting those acids to their acid chlorides (as described in Method A). Other types of in situ “activation” of the NSAID carboxyl are also satisfactory syntheses of the target carbonates. Carbonyldiimidazole, carbodiimides, or Mitsunobu conditions can catalyze the coupling of the 4-(hydroxymethyl)phenyl carbonates to the NSAID acids (as described in Method B). Yields tended to be lower from Method B compared to those obtained from the acid chlorides. A typical example (Example 14) follows.
-
- Diclofenac (0.83 mmol, 0.25 g) and 1,1′-carbonyldiimidazole (1.0 mmol, 0.16 g) were combined in dry CH2Cl2 (3 mL) and agitated with a magnetic stirrer for 30 min. 4-(Hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate (1.43 mmol, 0.32 g) in CH2Cl2 (2 mL) was added dropwise and the reaction was refluxed at 57° C. for 16 hr. Distilled water (30 mL) was added and the aqueous layer was extracted with CH2Cl2 (2×30 mL), washed with brine (60 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated to yield a crude yellow oil which was purified using column chromatography on silica gel with 85% hexane: 15% ethyl acetate as the eluent to yield 0.23 g of product as a clear oil.
- Clear viscous oil, 53%, Rf=0.47 (90% hexane: 10% ethyl acetate).
- 1H NMR (500 MHz, CDCl3): δ 7.31 (d, 2H, J=8.06 Hz), 7.23 (dd, 4H, J=8.67, 100.3 Hz), 7.21 (dd, 1H, J=1.43, 7.50 Hz), 7.13 (dt, 1H, J=1.53, 6.82 Hz), 6.95 (m, 2H), 6.84 (bs, 1H), 6.54 (d, 1H, J=8.03 Hz), 5.14 (s, 2H), 4.29 (t, 2H, J=7.54 Hz), 3.84 (s, 2H), 1.66 (t, 2H, J=7.62 Hz), 0.95 (s, 9H). Anal. Calcd. for C28H29Cl2NO5: C, 63.40; H, 5.51; N, 2.64. Found: C, 63.22; H, 5.45; N, 2.63.
- Following the procedure described for Example 14 but with the substitution of 4-(hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate instead of the 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate the title compound was prepared in 37% yield. Physical properties for the product appear below.
- Diclofenac (0.60 mmol, 0.18 g) and CDI (0.66 mmol, 0.11 g) were combined in dry CH2Cl2 (2 mL) and left stirring at room temperature for 30 min. 4-(Hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate (0.6 mmol, 0.16 g) in CH2Cl2 (2 mL) was added drop wise. The solution was stirred at room temperature for 3 days. Distilled water (30 mL) was added and the aqueous layer was extracted with CH2Cl2 (2×30 mL), washed with brine (60 mL) and dried over anhydrous magnesium sulfate. The solvent was evaporated to yield crude yellow oil which was purified using column chromatography with 80% hexane: 20% ethyl acetate as the eluent to yield 0.12 g of the product as a clear oil.
- Yield 37%, Rf=0.58 (90% hexane: 10% ethyl acetate).
- 1H NMR (500 MHz, CDCl3): δ 7.31 (d, 2H, J=8.07 Hz), 7.23 (dd, 4H, J=8.62, 101 Hz), 7.21 (dd, 1H, J=1.43, 7.54 Hz), 7.11 (dt, 1H, J=7.56 Hz), 6.95 (m, 2H), 6.84 (bs, 1H), 6.53 (d, 1H, J=8.02 Hz), 5.14 (s, 2H), 4.32 (t, 2H, J=8.40 Hz), 3.83 (s, 2H), 1.12 (t, 2H, J=8.94 Hz), 0.05 (s, 9H).
- Method A and Method B construct the target by synthetic sequences which build the final molecule through the key intermediacy of either a 4-(hydroxymethyl)phenyl 3,3-dimethylbutyl carbonate (5) or a 4-(hydroxymethyl)phenyl 2-(trimethylsilyl)ethyl carbonate (6). In both methods the NSAID acid is coupled to the benzylic hydroxyl in an ultimate step as an acid chloride (Method A) or as an in situ activated carboxylic acid (Method B). As a third alternative (Method C), one can take advantage of an initial selective esterification of an aliphatic carbinol in the presence of a phenol. In this fashion one can construct the NSAID ester to the hydroxymethylphenol in an initial step and react the remaining phenolic —OH to a chloroformate in a second step. In general, the overall yields by this method are inferior to those of Methods A or B. Example 16 demonstrates the Method C pathway.
- Although choline chloroformate [2-(trimethylammonium)ethyl chloroformate chloride salt] is readily available, we were unable to condense it with p-hydroxybenzaldehyde as described above in Step 2 under examples 5 or 6 and to obtain more than modest yields of the carbonate. Furthermore, the salt-like character of the trimethylammonium moiety thwarted a smooth hydride reduction of the formyl function to the requisite benzyl alcohol, in satisfactory yields. An alternative approach to this compound was required.
- Resort was made to the observation of Appendino [G. Appendino, A. Minassi, N. Daddario, F. Bianchi, and G. C. Tron, Organic Letters, 2002, 4 (22), 3839-3841] that a Mitsunobu reaction can selectively esterify the benzyl hydroxyl leaving the phenolic hydroxyl untouched in p-hydroxymethylphenol.
-
- To a pre-cooled (0° C.) solution of 0.19 g of p-hydroxybenzyl alcohol (1.5 mmol) and 0.31 g (1.5 mmol) of 2-(4-isobutylphenyl)propionic acid (ibuprofen) in dry THF (3.5 mL) were added 0.39 g TPP (1.5 mmol) and 295 μL DIAD (1.5 mmol). The reaction was slowly warmed to room temperature and left stirring under nitrogen atmosphere for 48 hr. Within 24 hr the reaction solution turned from yellow to red-orange to brown. The THF was evaporated to yield 0.94 g of a brown liquid. The liquid was re-dissolved in ethyl acetate, washed with saturated sodium bicarbonate, dried over anhydrous magnesium sulfate and chromatographed on a silica gel column with 60% hexane: 40% ethyl acetate to provide 42% of the benzyl ester. TLC with 80% hexane: 20% ethyl acetate indicated a single product spot and the absence of TPP, DIAD, or ibuprofen.
- 1H NMR confirmed the structure of this phenol and the material was used directly in the next synthetic step.
- Yield 42% product, Rf=0.21 (80% hexane: 20% ethyl acetate).
- 1H NMR, (CDCl3) δ 7.31 (d, 2H, J=8.5 Hz, meta-position to phenol), 7.27 (d, 2H, J=8.0 Hz, meta-position to isobutyl group), 7.12 (d, 2H, J=8.0 Hz, ortho-position to isobutyl group), 6.92 (d, 2H, J=8.5 Hz, ortho-position to phenol), 4.63 (s, 2H, —OCH2—Ar), 3.91 (q, 1H, J=7.0 Hz, —CH—(CH3)—CO—), 2.45 (d, 2H, J=7.0 Hz, (CH3)2CH—CH2—Ar), 1.84 (septet, 1H, J=6.75 Hz, (CH3)2CH—), 1.58 (d, 3H, J=7.0 Hz, Ar—CH(CH3)—CO—) and 0.89 ppm (d, 6H, J=6.5 Hz, (CH3)2—CH—).
-
- In a one-pot, three-step reaction, the phenol was chloroformylated, reacted with dimethylaminoethanol, and subsequently methylated. A 10 mL round bottom flask was charged with a stirring bar and 0.162 g of PVP (polyvinyl pyridine, 8.8 meq/g, 1.43 meq). The flask was placed under high vacuum for 45 min. The flask was filled with N2 and fitted with a rubber septum. Dry CH2Cl2 (800 μL) was introduced, and the resulting mixture was slowly stirred. A solution of phosgene in toluene (20% wt., d=0.94 g/mL, 0.188 g phosgene/mL solution, 899 μL) was added. The flask was placed under a positive N2 pressure and immersed in an ice bath. From Step 1 above, the ibuprofen benzyl ester of phenol (312.14 g/mol, 1.43 mmol, 445 mg) in 800 μL of dry CH2Cl2 was added drop wise to the cold and gently stirred mixture. The ice bath
- was removed after ten min. and the mixture was allowed to stir to room temperature overnight. The mixture was diluted with 4 mL of dry CH2Cl2 and purged with a stream of N2. The resin was removed by filtration through a flitted glass filter. The filtrate was then degassed using an aspirator fitted with an in-line drying tube. The solution was diluted to 10 mL with dry CH2Cl2, placed under a nitrogen atmosphere and immersed in an ice bath. 2-(Dimethylamino)ethanol (d=0.886 g/mL, 89.14 g/mol, 1.50 mmol), 133.5 mg, 151 μL) was added drop wise (neat) to the cold stirred solution. The ice bath was removed after 5 min. and the mixture was allowed to stir overnight. The reaction flask was again chilled in an ice bath and NEt3 (1 eq, 144 mg, 199 μL) was added. The reaction was allowed to continue overnight. The solvent was removed under reduced pressure, the crude residue dissolved in CH2Cl2 and the solution applied to a silica gel column with 96% CH2Cl2: 4% methanol as the moving phase. The appropriate fractions were combined and concentrated to an oil. This oil, the intermediate 4-[{2-(4-isobutylphenyl)propanoyloxy}methyl]phenyl 2-(dimethylammonium)ethyl carbonate, proved to be unstable decomposing on standing to a fully water-soluble solid. Because of its instability this intermediate was redissolved immediately in ether (10 mL) and stirred vigorously while methyl iodide (500 μL) was added. The mixture was stirred overnight, and the product was collected by centrifugation at 10,000 G for 10 min. The pellet was rinsed with fresh ether and centrifuged again. The ether was drawn off, and the product dried under a stream of N2, then under high vacuum. The yield was 123.9 mg or 22%., mp=106-110° C. decomposition with gas evolution.
- 1H NMR (CD3CN): δ 7.42-7.40 (m, 2H, meta-position on phenol), 7.30-7.29 (m, 2H, ortho to isobutyl substituent), 7.19-7.17 (m, 2H, meta to isobutyl substituent), 7.03-7.01 (m, 2H, ortho-position on phenol), 5.16 (s, 2H, Ar—CH2—O—CO—), 4.51-4.48 (m, 2H, —O—CH2CH2—), 3.989 (q, 1H, J=7.0 Hz, —CH(CH3)—CO—), 3.61-3.59 (m, 2H, —CH2—N+Me3), 3.09 (s, 9H, —N(CH3)3), 2.476 (d, 2H J=7.0 Hz, (CH3)2CH—CH2—Ar), 1.862 (septet, 1H, J=7.0 Hz, (CH3)CH—CH2—), 1.533 (d, 3H, J=7.0 Hz, —CH—CH3) and 0.886 (d, 6H, J=7.0 Hz, (CH3)2—CH—).
- Mass spec. calcd. for C26H36NO5: m/z=442.2593; observed, 442.2592.
- Previous work from these laboratories has described the synthesis of p-chloromethylphenyl carbonates which mimic a choline-like recognition feature (ref). We have shown that under some conditions a nucleophilic displacement by a carboxylate anion can generate a satisfactory yield of the NSAID-releasing agents revealed herein. An SN1-like pathway (carbonium ion promoted by silver ion) was unsuccessful but an SN2-like pathway (nucleophilic displacement mechanism) gave excellent yields. The generation of a carboxylate anion under low-polarity, anhydrous conditions with a toluene-soluble organic base makes this displacement possible. The anhydrous base DBU used in generation of carboxylic acid anions to promote SN2 reactions on alkyl halides has been shown to extend to NSAIDs (N. Ono, T. Yamada, T. Saito, K. Tanaka, and A. Kaji, Bull. Chem. Soc. Jpn. 1978, 51(8), 2401-2404).
-
- To 3.0 mL of DMF in which was dissolved 0.023 g (1.0 mmol) of 2-(2-methoxynaphthalene-6-yl)propanoic acid (naproxen), was added 0.017 g (1.0 mmol) of solid AgNO3. Gentle stirring for 4 hr at room temperature produced a solution. To this was added 0.029 g (1.0 mmol) of 4-(chloromethyl)phenyl 2-(trimethylsilyl)ethyl carbonate in 0.5 mL of DMF. Stirring was continued for additional 5 hr during which time aliquots were drawn from reaction mixture, added to water-ethyl acetate heterogeneous solution, and stirred for 1 min. The ethyl acetate layer of each such aliquot was used for TLC on silica gel plates which were conducted with a mobile phase of 20% ethyl acetate: 80% hexane. Intense new spots were observed at Rf 0.85, 0.75, and 0.15 with only the faintest hint (less than 5%) of authentic title product (Rf=0.55). This target compound was prepared in satisfactory yield by Method A (see Example 10) but was clearly available only in trace amounts by this variant of Method D.
-
- DBU (0.3 mmol, 0.05 g, 45 μL) was added to a solution of diclofenac (0.3 mmol, 0.09 g) in dry toluene (3 mL). The initially cloudy solution became clear but a white solid began to precipitate after 15 min of stirring at room temperature. To this was added drop wise a second solution of 0.36 mmol, 0.10 g, of the benzyl chloride analog in 3 mL of anhydrous toluene. The mixture was refluxed for 5 hr under argon atmosphere. After 30 min of refluxing, the solution turned yellow. Distilled water (20 mL) was added to the oily reaction mixture and the organic phase was extracted with methylene chloride (3×20 mL), washed with water and dried over anhydrous magnesium sulfate. The solvent was evaporated to yield crude yellow oil which was purified using silica gel column chromatography with 80% hexane: 20% ethyl acetate as the eluent to yield 0.10 g (61%) of clear oil product.
- Clear oil, 61% yield, Rf=0.58 (90% hexane: 10% ethyl acetate).
- 1H NMR (500 MHz, CDCl3): δ 7.31 (d, 2H, J=8.07 Hz), 7.23 (dd, 4H, J=8.62, 101 Hz), 7.21 (dd, 1H, J=1.43, 7.54 Hz), 7.11 (dt, 1H, J=7.56 Hz), 6.95 (m, 2H), 6.84 (bs, 1H), 6.53 (d, 1H, J=8.02 Hz), 5.14 (s, 2H), 4.32 (t, 2H, J=8.40 Hz), 3.83 (s, 2H), 1.12 (t, 2H, J=8.94 Hz), 0.05 (s, 9H).
- While inclusion of the p-hydroxybenzyl alcohol linker (for those molecules in which n=1 in Formula 1 and as described in Examples 7 to 18 herein) adds lipophilicity to the molecule and provides two sites of hydrolytic scission, a simpler construct where n=0 in Formula 1 also serves as a pro-drug controlled release platform. Herein we describe molecules of that set (specific examples 19 to 29).
- The appropriate NSAID (3.0 mmol), aliphatic alcohol (6 mmol) and DMAP (0.30 mmol) were combined in dry CH2Cl2 (6 mL) under nitrogen atmosphere. The solution was cooled to 0° C. and EDC (3.3 mmol) in CH2Cl2 (2 mL) was added. The solution was slowly warmed up to room temperature and left stirring overnight. Distilled water (80 mL) was added and the product was extracted with CH2Cl2 (2×80 mL), washed with saturated NaHCO3 and brine (160 mL each) and dried over MgSO4. Products were purified by passing crude material through a silica gel column using MeOH:CH2Cl2 (0.3-1.0% MeOH) as the eluent.
-
- Yellow oil, 96% yield; Rf=0.68 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.89 (s, 9H), 1.51-1.55 (t, 2H, J=7.50 Hz), 2.36 (s, 3H), 3.63 (s, 2H), 3.82 (s, 3H), 4.12-4.16 (t, 2H, J=7.35 Hz), 6.63-6.66 (dd, 1H, J=2.55, 9.00 Hz), 6.83-6.86 (d, 1H, J=8.95 Hz), 6.93-6.95 (d, 1H, J=2.50 Hz), 7.44-7.46 (m, 2H), 7.62-7.65 (m, 2H).
- Calc. for C25H28ClNO4 (441.95): C, 67.94; H, 6.39; N, 3.17. Found: C, 68.25; H, 6.48; N, 3.15.
-
- White solid, 94% yield; MP=92-94° C.; Rf=0.75 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.85 (s, 9H), 1.46-1.50 (t, 2H, J=7.45 Hz), 1.55 (d, 3H, J=7.15 Hz), 3.78-3.82 (m, 1H), 3.89 (s, 3H), 4.07-4.13 (m, 2H), 7.07-7.13 (m, 2H), 7.37-7.39 (dd, 1H, J=1.85, 8.45 Hz), 7.63-7.70 (m, 3H).
- Calc. for C20H26O3 (314.42): C, 76.40; H, 8.33. Found: C, 76.74; H, 8.14.
-
- Clear oil, 55% yield; Rf=0.83 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.90 (s, 9H), 1.56-1.60 (t, 2H, J=7.60 Hz), 3.77 (s, 2H), 4.16-4.20 (t, 2H, J=7.50 Hz), 6.52-6.54 (m, 1H), 6.91-6.98 (m, 3H), 7.08-7.12 (td, 1H, J=1.34, 7.18 Hz), 7.19-7.21 (m, 1H), 7.31-7.34 (d, 2H, J=8.05 Hz).
- Calc. for C20H23NO2Cl (380.31): C, 63.16; H, 6.10; N, 3.68. Found: C, 63.24; H, 5.95; N, 3.74.
-
- Clear liquid, 83% yield; Rf=0.95 (75% hexane: 25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.85 (s, 9H), 0.86-0.88 (d, 6H, J=6.60 Hz), 1.45-1.47 (d, 3H, J=4.95 Hz), 1.46-1.53 (m, 2H), 1.80-1.84 (m, 1H), 2.41-2.43 (d, 2H, J=7.20 Hz), 3.62-3.65 (m, 1H), 4.06-4.12 (m, 2H), 7.05-7.08 (d, 2H, J=8.10 Hz), 7.16-7.18 (d, 2H, J=8.05 Hz).
- Calc. for C19H30O2 (290.44): C, 78.57; H, 10.41. Found: C, 78.06; H, 10.22. (For 0.1 mol H2O: C, 78.03; H, 10.38).
-
- Yellow oil, 97% yield; Rf=0.64 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.00 (9H), 0.94-0.99 (m, 2H), 2.36 (s, 3H), 3.62 (s, 2H), 3.82 (s, 3H), 4.15-4.19 (m, 2H), 6.63-6.66 (dd, 1H, J=2.55, 9.00 Hz), 6.83-6.86 (d, 1H, J=8.95 Hz), 6.94-6.95 (d, 1H, J=2.50 Hz), 7.43-7.47 (m, 2H), 7.63-7.66 (m, 2H).
- Calc. for C24H28NO4ClSi (458.03): C, 62.94; H, 6.16; N, 3.06. Found: C, 63.07; H, 6.19; N, 3.05.
-
- Clear oil, 79% yield; Rf=0.94 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.00 (s, 9H), 0.96-1.00 (m, 2H), 3.74 (s, 2H), 4.17-4.19 (m, 2H), 6.49-6.51 (m, 1H), 6.88-6.96 (m, 3H), 7.05-7.09 (m, 1H), 7.17-7.19 (m, 1H), 7.29-7.31 (d, 2H, J=8.05 Hz).
- Calc. for C19H23NO2Cl2Si (396.39): C, 57.57; H, 5.85; N, 3.53. Found: C, 57.73; H, 5.91; N, 3.51.
-
- White solid, 80% yield; MP=81.5-82.5° C.; Rf=0.90 (75% hexane:25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.00 (s, 9H), 0.87-0.97 (m, 2H), 1.54-1.56 (d, 3H, J=7.20 Hz), 3.74-3.83 (m, 1H), 3.89 (s, 3H), 4.08-4.16 (m, 2H), 7.09-7.14 (m, 2H), 7.38-7.41 (dd, 1H, J=1.65, 8.48 Hz), 7.64-7.70 (m, 3H).
- Calc. for C19H26O3Si (330.50): C, 69.05; H, 7.93. Found: C, 69.18; H, 7.75.
-
- Clear liquid, 65% yield; Rf=0.96 (75% hexane: 25% ethyl acetate).
- 1H NMR (CDCl3): δ 0.00 (s, 9H), 0.86-0.90 (d, 6H, J=6.60 Hz), 0.88-0.96 (m, 2H), 1.44-1.47 (d, 3H, J=7.15 Hz), 1.79-1.85 (m, 1H), 2.41-2.43 (d, 2H, J=7.15 Hz), 3.61-3.66 (m, 1H), 4.06-4.16 (m, 2H), 7.05-7.08 (d, 2H, J=8.00 Hz), 7.16-7.19 (d, 2H, J=8.10 Hz).
- Calc. for C18H30O2Si (306.52): C, 70.53; H, 9.86. Found: C, 70.53; H, 9.72.
-
- Procedure derived from Schumann et al. Tetrahedron Lett. 2002, 43, 3507-3511. N,N-Dimethylaminoethanol (24 mmol, 2.40 mL) was dissolved in dry hexane (17 mL) under nitrogen atmosphere. The solution was cooled to 0° C. and n-butyl lithium (24 mmol, 15.1 mL [1.6 M in n-hexane] was added dropwise. The solution was slowly warmed up to room temperature and left stirring overnight. The solvent was evaporated and the crude product was recrystallized from hexane to yield yellow powder (1.35 g, 59%).
- Procedures for following two synthetic steps were derived from Venuti and Young Pharm. Res. 1989, 6, 867-873. (Procedure also included in EU Patent 0,289,262, Feb. 11, 1988.) It should be noted that all derivatives of this class (n=0, X═N+) are known compounds.
-
- The appropriate NSAID (4 mmol) was suspended in dry CH2Cl2 (15 mL). Triethylamine (4 mmol, 560 μL) was then added dropwise followed by 2-chloro-1-methyl-pyridinium iodide (4 mmol, 1.02 g). The mixture was left stirring at room temperature for 6 hr to allow for complete activation of the acid. The lithium salt of N,N-dimethylaminoethanol (4 mmol, 0.40 g) was then added and the resulting mixture was left stirring at room temperature for 2 days. 70 mL CH2Cl2 was added to the reaction mixture and the organic phase was washed with distilled water several times. A substantially pure product was isolated which was carried onto the next step without further purification.
-
- Methylation was carried out in an appropriate solvent (CH2Cl2, acetone, THF or diethyl ether) using excess CH3I (2 mL). The reaction was left stirring at room temperature overnight. Upon return, if an observable precipitate had not formed, an equal volume of ether was added and the pure product precipitated out of solution. The precipitate was filtered and washed with a small amount of cold ether.
-
- Yellow solid, 47% yield; MP=206-208° C.
- 1H NMR (500 MHz, MeOD): δ 2.33 (s, 3H), 3.08 (s, 9H), 3.65-3.68 (m, 2H), 3.79 (s, 3H), 3.84 (s, 2H), 4.53-4.56 (m, 2H), 6.66-6.70 (dd, 1H, J=2.50, 9.05 Hz), 6.85-6.89 (d, 1H, J=9.00 Hz), 7.00-7.01 (d, 1H, J=2.50 Hz), 7.54-7.58 (m, 2H), 7.64-7.67 (m, 2H).
- Calc. for C24H28N2O4ClI (570.85): C, 50.50; H, 4.94; N, 4.91. Found: C, 49.92; H, 4.93; N, 4.87. (with 0.15 mol H2O: C, 50.25; H, 4.97; N, 4.88).
-
- White solid, 44% yield; MP=202-204° C.
- 1H NMR (500 MHz, MeOD): δ 1.55-1.57 (d, 3H, J=7.15 Hz), 2.93 (s, 9H), 3.3.50-3.67 (m, 2H), 3.88 (s, 3H), 3.90-3.97 (m, 1H), 4.40-4.60 (m, 2H), 7.10-7.13 (dd, 1H, J=2.50, 8.93 Hz), 7.19-7.20 (d, 1H, J=2.45 Hz), 7.35-7.39 (dd, 1H, J=1.85, 8.50 Hz), 7.68-7.75 (m, 3H).
- Calc. for C19H26NO3I (443.32): C, 51.48; H, 5.91; N, 3.16. Found: C, 51.54; H, 5.96; N, 3.07.
-
- White solid, 18% yield; MP=113-114° C.
- 1H NMR (MeOD): δ 0.86-0.88 (d, 6H, J=5.10 Hz), 1.45-1.49 (d, 3H, J=7.15 Hz), 1.78-1.83 (m, 1H), 2.42-2.44 (d, 2H, J=7.15 Hz), 3.00 (s, 9H), 3.55-3.83 (m, 2H), 4.08 (s, 1H), 4.37-4.56 (m, 2H), 7.09-7.12 (m, 2H), 7.18-7.23 (m, 2H).
- Calc. for C18H30NO2I (419.34): C, 51.56; H, 7.21; N, 3.34. Found: C, 49.41; H, 7.09; N, 3.59. (with 0.75 mol H2O: C, 49.94; H, 7.33; N, 3.24).
- Acetyl cholinesterase Inhibition Methodology
- Acetyl cholinesterase (Type V-S from Electrophorus electricus), acetyl thiocholine iodide (ACM), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and tacrine hydrochloride were obtained from Sigma-Aldrich (Saint Louis, Mo.). Methanol for the preparation of stock solutions was obtained from EMD Chemicals. Cholinesterase inhibition was assayed spectrophotometrically at 412 nm according to the method of Ellman (Biochem. Phamacol. 1961, 7: 88-95). Assays were performed in polystyrene 96-well plates (Corning 96-well flat transparent) and a conventional micro-plate reader was employed (Tecan's
Infinite 200 multimode). The assay procedures were as follow: 200 μL of 0.5 mM DTNB in 100 mM sodium phosphate buffer (pH 8), 30 μL of inhibitor stock solution prepared in methanol, 50 μL of 3 mM AChI and 20 μL of 1.25 u/mL AChE prepared respectively inphosphate buffer 100mM pH 8 and 20 mM pH 7. Immediately after the enzyme was added the signal was measured at 30 s intervals over 5 min at 25° C. Percentage inhibition was calculated relative to a control sample (methanol). The background signal was measured in control wells containing all the reagents except AChE. IC50 values were obtained from a minimum of eight concentrations in duplicate and by fitting the experimental data with a dose-response curve using a curve fitting software (Prism Version 5.00, GraphPad Software, San Diego, Calif.). IC50 values from 0.51 to 2.29 μM were measured for the NSAID ester-carbonates of the trimethylsilyl and the t-butyl choline analogs (viz Examples 7-15) and of 77.7 μM for the true choline species (Example 16). The best inhibitor in the NSAID ester-carbonate set (see Table 1) has an IC50 only ten-times higher than that of the clinical standard AChE inhibitor, tacrine hydrochloride. The NSAID esters (examples 19-29) inhibited AChE on the micromolar to milimolar scale (see Table 2), they were found less active than their ester-carbonate analog (i.e., the molecules containing the p-functionalized benzyl alcohol, examples 7-18) by at least a factor of 4. The most potent NSAID ester (Example 24) inhibited AChE at 2.66 μM, a value within the range of other known inhibitors. As in the ester-carbonate series, the true choline analogues (i.e., those with N+) of the NSAID ester series (Examples 27, 28 and 29) were less potent inhibitors with IC50 values ranging from 0.23 to 3.4 mM. - Inactivated enzyme was obtained by incubating 20 units of enzyme in 1 mL phosphate buffer (20 mM, pH 7) with 55 μL of the inhibitor. Stock solution of inhibitors were prepared in methanol and the final concentration of inhibitor was 52 μM. A control incubation (methanol) was run with the enzyme in absence of the inhibitor. After 30 minutes of incubation at 25° C., an aliquot of 500 μL was applied to a standardized Sephadex G-25 Medium (PD MiniTrap™) and eluted with 100 mM sodium phosphate buffer (pH 7) containing 0.1
% triton 100× in order to maintain enzyme activity. Protein content was assayed using a micro BCA Protein Assay kit (ThermoScientific). Recovery of enzyme activity suggesting reversible inhibition was demonstrated by the Ellman's method previously described (results shown in Table 3). - To determine the type of inhibition of AChE, kinetic inhibition studies were performed and the results plotted by the Lineweaver-Burk method (H. U. Bergmeyer and K. Gawehn, “Principles of Enzymatic Analysis,” Verlag Chemie, NY, 1978, pp. 36-40). The kinetics were generated by using a fixed amount of enzyme (0.025 units) and varying both amounts of substrate (1000 to 50 μM final concentrations) and inhibitor (1 to 100 μM final concentration). Experiments were carried out in duplicate or triplicate with the analysis performed by the Ellman method previously described.
FIG. 2 displays the results from Example 9 and Example 22. - Single or multiple intersection points located in quadrant III or abscissa of the five double-reciprocal rate lines marks these reactions as reversible non-competitive inhibition (V. Leskovac, “Comprehensive Enzyme Kinetics”, Kluwer Academic/Plenum Publishers, NY, 2003, pp. 99-102). This precise type non-competitive inhibition has also been observed in other AChE inhibitor families including decamethonium and the semi-synthetic steroidal alkaloids from Buxus balearica. (T. Sauvaitre, M. Barlier, D. Herlem et al., J. Med. Chem. 2007, 50: 5311-5323). Similar behavior was observed for other NSAID ester and ester-carbonate pro-drugs. These findings reinforce the claim of reversibility supported by the recovery of enzyme activity from inhibited enzyme following Sephadex chromatography.
- Hydrolysis of the inhibitors was carried out at 37° C. under constant stirring. Pro-drug was added to an aqueous potassium carbonate (10 eq) solution containing 20% DMSO v/v for a final concentration in prodrug of 0.5 mg/mL. Aliquots of the reaction were withdrawn periodically and diluted by 2 with acetonitrile prior HPLC analysis. Samples were injected onto a C18 reverse phase column (Agilent Eclipse C18 4.6×150 mm, 35° C., 20 μL injection, UV detection at 230 and 267 nm, flow rate 0.5 ml/min, post time 5 min). A gradient method was run with mobile phase A: 0.1% TFA in water and B: Acetonitrile,
method 0 to 2 minutes: 80% A, 2 to 15 minutes: 80% to 15%, 15 to 25: 15%, 25 to 30 minutes: 15% to 80%. Authentic standards of the parent pro-drugs, the NSAID, and the 4-hydroxybenzyl alcohol were obtained and used for comparison. For a typical chromatograph obtained with the pro-drug Example 9 and after 2 hr seeFIG. 1 . The release of both the NSAID Naproxen and the 4-hydroxybenzylalcohol suggested both cleavages at the ester and carbonate bond. - Hydrolysis rates in aqueous solution were determined in saline phosphate buffer (PBS, pH 7.4). Methanol (up to 50%) was used as a co-solvent to effect solution and to prevent precipitation over time. After vortexing, pro-drug solutions (˜50-75 μM) were incubated at 37° C. At regular intervals, samples of the reaction mixture were withdrawn, diluted by two with acetonitrile and analyzed by HPLC (see description below). Remaining pro-drug and NSAID released were monitored by single determination. Half-life times (hr) in aqueous solutions were determined by plotting the semi-log of either pro-drug disappearance or of drug released (
FIG. 3 ). Half-life values for several example molecules are included in Table 4. Hydrolysis of the parent drug and subsequent release of the NSAID was observed under physiological pH 7.4. HPLC method—Agilent Eclipse XDB-C18 column (5 μm, 4.6×150 mm); mobile phase: water (A) and acetonitrile (B) containing 0.1% TFA; flow rate: 1.5 mL/min; gradient increase from A/B:80/20 to 30/70 over 10 min, to 10/90 over 15 min, return to initial condition in 5 min, post-time run 5 min; injection: 25 μL detector wavelength 210 nm. - The rate of hydrolysis for pro-drugs was determined at 37° C. in fresh human plasma diluted to 80% with PBS (pH 7.4). Human plasma was obtained from the pooled, heparininised blood of healthy donors and was frozen and stored at −80° C. prior to use. Test compounds (20 μL, 1 mM in DMSO) were added to pre-heated plasma (960 μL) and mixed gently at 300 rpm. DMSO reached 2% volume content. At suitable intervals, aliquots of 100 μL were withdrawn and 200 μL of cold precipitation buffer (90/10 acetonitrile/water with 0.1% formic acid) were added to precipitate proteins from the serum. The resulting mixture was filtered through a Mini-Uniprep™ filter (Whatman, PVDF membrane, 0.45 μm) and the filtrate was analyzed by HPLC (, see description below). Remaining pro-drug and NSAID released was monitored by single determination at 230 or 277 nm. Half-life times for example compounds in plasma are shown in Table 4. All prodrugs tested show NSAID-release with half-lives not exceeding 8 hr. For a typical chromatograph obtained with Example 14 after 12.5 hr incubation see
FIG. 3 . HPLC method—Agilent high resolution XDB-C18 column (1.8 μm, 4.6×50 mm); mobile phase: water (A) and methanol (B) containing 0.1% formic acid; flow rate: 0.8 mL/min; gradient increase from A/B:70/30 to 30/70 over 8 min, 30/70 to 10/90 over 4 min, 10/90 to 5/95 over 4 min, 5/95 to 70/30 over 4 min, post-time 5 min; injection: 25 μL; UV detection 230 and 277 nm. -
TABLE 1 Anticholinesterase activity of NSAID carbonates (n = 1, X = C, Si, N+). NSAID series Example # X IC50 (μM) Ibuprofen 7 C 1.93 ± 0.64 8 Si 1.19 ± 0.20 16 N+ 77.7 ± 0.8 Naproxen 9 C 1.74 ± 1.01 10 Si 0.83 ± 0.15 Indomethacin 12 C 2.29 ± 0.94 13 Si 0.72 ± 0.13 Diclofenac 14 C 0.51 ± 0.02 15 Si 1.36 ± 0.13 Reference Tacrine HCl — 0.055* ± 0.005 *Literature value for tacrine HCl IC50 0.039 μM (J. Med. Chem. 2001, 44, 2707-2718). -
TABLE 2 Anticholinesterase activity of NSAID esters (n = 0, X = C, Si, N+). NSAID Series Example # X IC50 (μM) Ibuprofen 22 C 24.57 ± 14.5 26 Si 25.67 ± 4.85 29 N+ 3376 ± 2650 Naproxen 20 C 19.65 ± 1.70 25 Si 13.88 ± 0.26 28 N+ 907.4 ± 387 Indomethacin 19 C 9.75 ± 0.89 23 Si 3.32 ± 0.36 27 N+ 230.3 ± 32.3 Diclofenac 21 C 2.69 ± 0.15 24 Si 2.66 ± 0.25 -
TABLE 3 AChE Activity Recovery After Inactivation Inhibitor % Enzyme Activitya noneb 100 Example 7 109 Example 9 95 Example 14 95 Example 21 95 Example 20 113 Tacrine HCl 95 aEnzyme activity was assayed after 30 min incubation with 52 μM inhibitor which deactivated the enzyme. Subsequent chromatography over Sephadex gel resulted in near-complete restoration of activity. bControl without inhibitor present. -
TABLE 4 Half-Lives of NSAID Prodrugs in PBS and Plasma at 37° C. Example # t1/2 (hr)a t1/2 (hr)b 7 20.4 3.33 9 nd 2.23 12 nd 7.80 14 6.95 5.93 21 105 nd aIn PBS (pH 7.4) Buffer. bIn diluted human plasma. nd: Half-life not determined. - The mouse ear vesicant model (MEVM) was used to assess the anti-inflammatory activity of dual action therapeutics. In this assay, sulfur mustard or a sulfur mustard analog is applied topically to the ears of female CD-1 mice (24-25 days old) in 20 μL of dichloromethane or acetone to generate an inflammatory response. This is evident by the appearance of edema in the mouse ears. Edema was measured by increases in the wet weight of ear punch biopsies. Control mice received dichloromethane or acetone without the mustard. To evaluate drugs, ears were pretreated with 20 μL of vehicle control (dichloromethane or acetone) or 20 μL of
test compounds 20 min prior to treatment with the sulfur mustard. For our studies, 2-chloroethyl ethyl sulfide, a model sulfur mustard vesicant was used. Then, five hr later, all mice were sacrificed. The ear punches (6 mm in diameter) were taken and weighed. Data was analyzed as percent inhibition of vesicant-induced edema. - As an alternative, the TPA (12-O-tetradecanoylphorbol-13-acetate)-induced ear edema assay was carried out to examine anti-inflammatory activity of dual functional therapeutics in a skin inflammation model. The female CD-1 mice (24-25 days old) were topically treated with 20 μl, of acetone or dual functional therapeutic in 20 μL of acetone at 20 min before topical application of 20 μL of acetone or TPA (1 nmol) in 20 μL of acetone. Then, five hr later, all mice were sacrificed and ear punches (6 mm in diameter) were taken and weighed.
- Comparable results were observed from either inflammatory challenge method and Table 5 displays sample findings. Suppression percentages varied from 38 to 95% across the set of compounds.
-
TABLE 5 Anti-Inflammatory Results from MEVM Example # Suppression of CEES 7 52% 12 54% 13 85% 14 93% 25 55% 26 50% 29 38% - AChE acetylcholine esterase
AChI acetylthiocholine iodide
CDI 1,1′-carbonyldiimidazole
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
DCC dicyclohexylcarbodiimide
DIAD diisopropyl azodicarboxylate
DMAP 4-(dimethylamino)pyridine - DTNB 5,5′-dithiobis(2-nitrobenzoic acid)
EDC, 1-[3-(dimethylamino)propyl]-3-ethylcarbodimide methiodide
NSAID non-steroidal anti-inflammatory agent
MEVM mouse ear vesicant model
PVP polyvinylpyridine
Rf Retention factor; ratio of distance migrated on TLC by a compound over the -
- distance to the solvent front
RPM revolutions per minute
THF tetrahydrofuran
TLC thin layer chromatography on silica coated glass plates
TPA 12-O-tetradecanoylphorbol-13-acetate
TPP triphenylphosphine
- distance to the solvent front
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/127,284 US20120010168A1 (en) | 2008-11-03 | 2009-11-03 | Unique Dual-Action Therapeutics |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19814708P | 2008-11-03 | 2008-11-03 | |
US13/127,284 US20120010168A1 (en) | 2008-11-03 | 2009-11-03 | Unique Dual-Action Therapeutics |
PCT/US2009/005971 WO2010051044A1 (en) | 2008-11-03 | 2009-11-03 | Unique dual-action therapeutics |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/005971 A-371-Of-International WO2010051044A1 (en) | 2008-11-03 | 2009-11-03 | Unique dual-action therapeutics |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/365,088 Division US10570161B2 (en) | 2008-11-03 | 2016-11-30 | Unique dual-action therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120010168A1 true US20120010168A1 (en) | 2012-01-12 |
Family
ID=42129175
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/127,284 Abandoned US20120010168A1 (en) | 2008-11-03 | 2009-11-03 | Unique Dual-Action Therapeutics |
US15/365,088 Active - Reinstated 2029-12-21 US10570161B2 (en) | 2008-11-03 | 2016-11-30 | Unique dual-action therapeutics |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/365,088 Active - Reinstated 2029-12-21 US10570161B2 (en) | 2008-11-03 | 2016-11-30 | Unique dual-action therapeutics |
Country Status (2)
Country | Link |
---|---|
US (2) | US20120010168A1 (en) |
WO (1) | WO2010051044A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150297718A1 (en) * | 2014-04-17 | 2015-10-22 | Guang Yan | Iontophoresis delivery of cationic prodrugs for topical treatment of musculoskeletal or skin diseases |
US20150324091A1 (en) * | 2012-04-28 | 2015-11-12 | Li-Mei Jiao | Detecting valuable sections in webpage |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107903283A (en) * | 2017-12-04 | 2018-04-13 | 武汉药明康德新药开发有限公司 | By trimethyl(Vinyl)The method that silane synthesizes 2 phenyl, 2 trimethyl silicon substrate chloroacetic chloride |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983178A (en) | 1975-07-21 | 1976-09-28 | Hooker Chemicals & Plastics Corporation | Immonium salts and derivatives thereof |
US4206310A (en) * | 1975-09-27 | 1980-06-03 | Sumitomo Chemical Company, Limited | Process for the preparation of esters |
DE3223949A1 (en) | 1982-06-26 | 1983-12-29 | Celamerck Gmbh & Co Kg, 6507 Ingelheim | THIOLPHOSPHORIC ACID ESTERS, THEIR PRODUCTION AND USE |
US5082964A (en) * | 1984-02-01 | 1992-01-21 | Lehigh University | Selective acetylcholinesterase inhibitors and methods of making and using same |
AU1508988A (en) | 1987-04-27 | 1988-10-27 | Syntex Pharmaceuticals International Ltd. | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US20020160988A1 (en) * | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
WO2004017967A1 (en) * | 2002-08-22 | 2004-03-04 | Cornell Research Foundation, Inc. | Multifunctional cox-2 inhibitors |
US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
US20050234244A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Synthesis of COX-2 and FAAH inhibitors |
KR100683034B1 (en) * | 2004-11-16 | 2007-02-15 | 에스케이케미칼주식회사 | Method for preparing unsymmetric linear carbonate |
-
2009
- 2009-11-03 US US13/127,284 patent/US20120010168A1/en not_active Abandoned
- 2009-11-03 WO PCT/US2009/005971 patent/WO2010051044A1/en active Application Filing
-
2016
- 2016-11-30 US US15/365,088 patent/US10570161B2/en active Active - Reinstated
Non-Patent Citations (1)
Title |
---|
Farias et al. 2005, Neurobiology of disease, Volume 18, pages 176-183. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150324091A1 (en) * | 2012-04-28 | 2015-11-12 | Li-Mei Jiao | Detecting valuable sections in webpage |
US20150297718A1 (en) * | 2014-04-17 | 2015-10-22 | Guang Yan | Iontophoresis delivery of cationic prodrugs for topical treatment of musculoskeletal or skin diseases |
Also Published As
Publication number | Publication date |
---|---|
US10570161B2 (en) | 2020-02-25 |
US20170143836A1 (en) | 2017-05-25 |
WO2010051044A1 (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11136342B2 (en) | Carbonate prodrugs and methods of using the same | |
US10570161B2 (en) | Unique dual-action therapeutics | |
Fan et al. | Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen | |
EP0112130A1 (en) | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids, their preparation and use | |
SK100399A3 (en) | Lipophilic derivatives of biologically active compounds, process for producing the same and pharmaceutical composition containing same | |
Leppänen et al. | Design and synthesis of a novel L-dopa− entacapone codrug | |
Carvalho et al. | Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes | |
KR20160072252A (en) | Novel dgat2 inhibitors | |
US10752582B2 (en) | Augmenting moieties for anti-inflammatory compounds | |
KR101748229B1 (en) | 2,2'-bis-thiazole-based compounds, preparation method therefor and use thereof | |
Liu et al. | Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs | |
JP4570463B2 (en) | Medicine for chronic pain | |
US7173018B2 (en) | Phospholipid derivatives of non-steroidal anti-inflammatory drugs | |
US9422233B2 (en) | Vanilloid fatty hydroxamates as therapeutic anti-inflammatory pharmaceuticals | |
Fadl et al. | Paracetamol (acetaminophen) esters of some non-steroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index | |
US9512068B2 (en) | Augmenting moieties for anti-inflammatory compounds | |
US20240150279A1 (en) | C prime agents for treating metabolic disorders | |
US11731991B2 (en) | Augmenting moieties for anti-inflammatory compounds | |
CN117736201A (en) | Targeted histone deacetylase 8 proteolytic chimera, preparation method and application thereof | |
NON-STEROIDAL | 4, Inflammopharmacology, 1998; 6: 143–157, mm (C) 1998 Kluwer Academic Publishers. Printed in the Netherlands | |
NL8003292A (en) | Pivaloyl:oxy:methyl 2-propyl-pentanoate - useful as anti:epileptic and anticonvulsant (AT 15.5.81) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RUTGERS, THE STATE UNIVERSITY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HECK, DIANE;HUANG, MOU-TUAN;SIGNING DATES FROM 20111017 TO 20111109;REEL/FRAME:027339/0618 |
|
AS | Assignment |
Owner name: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LASKIN, JEFFREY;REEL/FRAME:028788/0665 Effective date: 20120605 |
|
AS | Assignment |
Owner name: LEHIGH UNIVERSITY, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FABIO, KARINE;MOHANTA, PRAMOD;LACEY, C. JEFFREY;AND OTHERS;SIGNING DATES FROM 20121212 TO 20130112;REEL/FRAME:029740/0683 |
|
AS | Assignment |
Owner name: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NEW J Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY;REEL/FRAME:033525/0369 Effective date: 20130628 |
|
AS | Assignment |
Owner name: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, NEW J Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY;REEL/FRAME:034654/0200 Effective date: 20130628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |